<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?all-math-mml yes?><?use-mml?><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName nihms2pmcx2.xsl?><?ConverterInfo.Version 1?><?properties manuscript?><?origin nihpa?><?iso-abbr Cell Rep?><?submitter-system nihms?><?submitter-userid 9560183?><?submitter-authority eRA?><?submitter-login tschang3?><?submitter-name Timothy Chang?><?domain nihpa?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">101573691</journal-id><journal-id journal-id-type="pubmed-jr-id">39703</journal-id><journal-id journal-id-type="nlm-ta">Cell Rep</journal-id><journal-id journal-id-type="iso-abbrev">Cell Rep</journal-id><journal-title-group><journal-title>Cell reports</journal-title></journal-title-group><issn pub-type="epub">2211-1247</issn></journal-meta><article-meta><article-id pub-id-type="pmcid">8221021</article-id><article-id pub-id-type="pmid">32579933</article-id><article-id pub-id-type="doi">10.1016/j.celrep.2020.107807</article-id><article-id pub-id-type="manuscript">nihpa1710525</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Identification of Conserved Proteomic Networks in Neurodegenerative Dementia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Swarup</surname><given-names>Vivek</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A7">7</xref><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Timothy S.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Duong</surname><given-names>Duc M.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dammer</surname><given-names>Eric B.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dai</surname><given-names>Jingting</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lah</surname><given-names>James J.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Erik C.B.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Seyfried</surname><given-names>Nicholas T.</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Levey</surname><given-names>Allan I.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Geschwind</surname><given-names>Daniel H.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A9">9</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA</aff><aff id="A2"><label>2</label>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA</aff><aff id="A3"><label>3</label>Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA</aff><aff id="A4"><label>4</label>Department of Neurology, Second Xiangya Hospital, Central South University, Changsha, China</aff><aff id="A5"><label>5</label>Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA</aff><aff id="A6"><label>6</label>Institute of Precision Health, University of California, Los Angeles, Los Angeles, CA 90095, USA</aff><aff id="A7"><label>7</label>Present address: Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92697, USA</aff><aff id="A8"><label>8</label>These authors contributed equally</aff><aff id="A9"><label>9</label>Lead Contact</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">AUTHOR CONTRIBUTIONS</p><p id="P2">Conceptualization, V.S., T.S.C., J.J.L., E.C.B.J., N.T.S., A.I.L., and D.H.G.; Methodology, V.S., T.S.C., D.M.D., E.B.D., J.D., N.T.S., A.I.L., and D.H.G.; Software, V.S. and T.S.C.; Formal Analysis, V.S., T.S.C., D.M.D., and E.B.D.; Investigation, D.M.D. and E.B.D.; Resources, J.J.L., E.C.B.J, N.T.S., A.I.L., and D.H.G.; Data Curation, V.S.; Writing &#x02013; Original Draft, V.S., T.S.C., and D.H.G.; Writing &#x02013; Review &#x00026; Editing, V.S., T.S.C., J.L., E.C.B.J., N.T.S., A.I.L., and D.H.G.; Visualization, V.S. and T.S.C.; Supervision, N.T.S., A.I.L., and D.H.G.; Funding Acquisition, N.T.S., A.I.L., and D.H.G.</p></fn><corresp id="CR1"><label>*</label>Correspondence: <email>dhg@mednet.ucla.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>16</day><month>6</month><year>2021</year></pub-date><pub-date pub-type="ppub"><day>23</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>6</month><year>2021</year></pub-date><volume>31</volume><issue>12</issue><fpage>107807</fpage><lpage>107807</lpage><!--elocation-id from pubmed: 10.1016/j.celrep.2020.107807--><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p></license></permissions><abstract id="ABS1"><title>SUMMARY</title><p id="P3">Data-driven analyses are increasingly valued in modern medicine. We integrate quantitative proteomics and transcriptomics from over 1,000 post-mortem brains from six cohorts representing Alzheimer&#x02019;s disease (AD), asymptomatic AD, progressive supranuclear palsy (PSP), and control patients from the Accelerating Medicines Partnership &#x02013; Alzheimer&#x02019;s Disease consortium. We define robust co-expression trajectories related to disease progression, including early neuronal, microglial, astrocyte, and immune response modules, and later mRNA splicing and mitochondrial modules. The majority of, but not all, modules are conserved at the transcriptomic level, including module C3, which is only observed in proteome networks and enriched in mitogen-activated protein kinase (MAPK) signaling. Genetic risk enriches in modules changing early in disease and indicates that AD and PSP have distinct causal biological drivers at the pathway level, despite aspects of similar pathology, including synaptic loss and glial inflammatory changes. The conserved, high-confidence proteomic changes enriched in genetic risk represent targets for drug discovery.</p></abstract><abstract id="ABS2" abstract-type="graphical"><title>Graphical Abstract</title><p id="P4"><graphic xlink:href="nihms-1710525-f0007.jpg" position="anchor" orientation="portrait"/></p></abstract><abstract id="ABS3" abstract-type="summary"><title>In Brief</title><p id="P5">Swarup et al. use a multi-omic, multi-cohort approach to identify robust early and late proteomic changes in AD and other neurodegenerative dementias and find that genetic risk is differentially enriched across disorders. Shared co-expression modules showing consistent molecular alterations at multi-omic levels are ripe for future investigation as drug targets.</p></abstract></article-meta></front><body><sec id="S1"><title>INTRODUCTION</title><p id="P6">Dementia affects 9% of the population (<xref rid="R68" ref-type="bibr">Langa et al., 2017</xref>; <xref rid="R81" ref-type="bibr">McKhann et al., 2011</xref>) and exacts a large societal and financial burden (<xref rid="R3" ref-type="bibr">Alzheimer&#x02019;s Association, 2019</xref>). The most common dementia is Alzheimer&#x02019;s disease (AD), characterized pathologically by neurofibrillary tangles, consisting of filamentous hyperphosphorylated microtubule-associated protein tau (<italic>MAPT</italic>; tau), inclusions, and senile plaques, consisting of A&#x003b2; deposits (<xref rid="R24" ref-type="bibr">De Strooper and Karran, 2016</xref>; <xref rid="R40" ref-type="bibr">Goate et al., 1991</xref>; <xref rid="R66" ref-type="bibr">Lage et al., 2007</xref>; <xref rid="R106" ref-type="bibr">Schneider et al., 2009</xref>; <xref rid="R117" ref-type="bibr">Vinters, 2015</xref>). Several neurodegenerative conditions are related to AD due to shared alterations in proteostasis and pathological protein aggregates in brain including progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), and Parkinson&#x02019;s disease (PD) (<xref rid="R5" ref-type="bibr">Arendt et al., 2016</xref>; <xref rid="R19" ref-type="bibr">Cummings, 2003</xref>; <xref rid="R29" ref-type="bibr">Erkkinen et al., 2018</xref>; <xref rid="R65" ref-type="bibr">Kovacs, 2015</xref>). Although common and rare genetic variants in <italic>MAPT</italic> cause or increase the risk for AD, PSP (<xref rid="R16" ref-type="bibr">Coppola et al., 2012</xref>; <xref rid="R25" ref-type="bibr">Desikan et al., 2015</xref>), FTD, and PD, the risk for these disorders is heterogeneous and complex (<xref rid="R13" ref-type="bibr">Chang et al., 2017</xref>; <xref rid="R14" ref-type="bibr">Chen et al., 2018</xref>; <xref rid="R31" ref-type="bibr">Ferrari et al., 2014</xref>; <xref rid="R61" ref-type="bibr">Karch and Goate, 2015</xref>; <xref rid="R107" ref-type="bibr">Seelaar et al., 2011</xref>). So, despite advances in identifying genetic contributions to dementia disease risk, understanding how risk factors may converge on specific molecular pathways remains a critical gap in our knowledge (<xref rid="R9" ref-type="bibr">Bonham et al., 2018</xref>; <xref rid="R92" ref-type="bibr">Parikshak et al., 2015</xref>).</p><p id="P7">A powerful approach to provide a data-driven framework for connecting genetic risk to disease pathways is gene network analysis, which leverages gene co-expression to improve mechanistic models of pathophysiology (<xref rid="R92" ref-type="bibr">Parikshak et al., 2015</xref>). To accelerate this process, the National Institutes of Health (NIH) developed the Target Identification and Preclinical Validation Project of the Accelerating Medicines Partnership &#x02013; Alzheimer&#x02019;s Disease (AMP-AD) consortium (<xref rid="R50" ref-type="bibr">Hodes and Buckholtz, 2016</xref>) to integrate high-throughput genomic and molecular data from disease brain within a network-driven structure (<xref rid="R50" ref-type="bibr">Hodes and Buckholtz, 2016</xref>; <xref rid="R76" ref-type="bibr">Logsdon et al., 2019</xref>). Within this context, several large-scale RNA sequencing (RNA-seq) projects have been conducted (<xref rid="R2" ref-type="bibr">Allen et al., 2018</xref>; <xref rid="R22" ref-type="bibr">De Jager et al., 2018</xref>; <xref rid="R34" ref-type="bibr">Gaiteri et al., 2016</xref>; <xref rid="R76" ref-type="bibr">Logsdon et al., 2019</xref>; <xref rid="R86" ref-type="bibr">Mostafavi et al., 2018</xref>; <xref rid="R102" ref-type="bibr">Readhead et al., 2018</xref>; <xref rid="R127" ref-type="bibr">Zhang et al., 2013</xref>), identifying transcriptomic changes in the cerebral cortex from patients with AD and showing that genetic risk for AD, rather than being widely distributed, is enriched in specific transcriptomic networks. Complementary approaches based on proteomics quantified several thousand proteins and identified AD-related proteomic networks in post-mortem brain, but most have been limited to a single cohort (<xref rid="R57" ref-type="bibr">Johnson et al., 2018</xref>; <xref rid="R80" ref-type="bibr">McKenzie et al., 2017</xref>; <xref rid="R97" ref-type="bibr">Ping et al., 2018</xref>; <xref rid="R108" ref-type="bibr">Seyfried et al., 2017</xref>; <xref rid="R125" ref-type="bibr">Yu et al., 2018</xref>; <xref rid="R129" ref-type="bibr">Zhang et al., 2018</xref>).</p><p id="P8">Here, we took an integrative systems biology approach to identify neurodegenerative dementia-associated protein networks in post-mortem brain across multiple AD cohorts (<xref rid="R50" ref-type="bibr">Hodes and Buckholtz, 2016</xref>). To detect robust disease-associated changes, we used the same processing scheme to harmonize data across studies and applied a consensus network analysis approach to identify conserved co-expression modules (<xref rid="R70" ref-type="bibr">Langfelder and Horvath, 2008</xref>; <xref rid="R72" ref-type="bibr">Langfelder et al., 2013</xref>; <xref rid="R115" ref-type="bibr">Swarup et al., 2019</xref>). We subsequently characterized the temporal trajectories of distinct biological processes over disease progression by distinguishing early and late disease changes and identifying several co-expression modules correlated with neuropathology and cognitive decline. We validated these findings in an orthogonal dataset (<xref rid="R97" ref-type="bibr">Ping et al., 2018</xref>) and extended our initial findings across multiple neurodegenerative diseases, including FTD with TDP-43 (FTD-TDP), PSP with corticobasal degeneration (PSP-CBD), PD, PD with dementia (PD-D), multiple system atrophy (MSA), and amyotrophic lateral sclerosis (ALS). We found protein co-expression modules that were dysregulated in neurodegenerative dementias (AD, FTD-TDP, PSP-CBD, and PD-D), but not in related neurodegenerative diseases (PD, MSA, and ALS) where dementia is not the defining feature. We evaluated concordance of transcriptomic and proteomic signatures in a subset of samples, finding high correspondence overall, as well as proteome-specific changes. To understand the relationship of these core molecular processes with causal genetic drivers, we placed common variants associated with disease risk within co-expression modules to identify specific biological processes enriched in disease-specific risk variants.</p></sec><sec id="S2"><title>RESULTS</title><p id="P9">Label-free high-throughput quantitative proteomics by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was performed on five different study cohorts&#x02014;the Baltimore Longitudinal Study of Aging (BLSA), Adult Changes of Thought (ACT), Mount Sinai Brain Bank (MSBB), Banner Sun Health Research Institute (Banner), and Mayo Clinic Brain Bank (Mayo; <xref rid="F1" ref-type="fig">Figure 1</xref>)&#x02014;totaling 798 samples representing AD, asymptomatic AD (AsymAD), PSP, and controls from prefrontal and temporal cortex (<xref rid="F1" ref-type="fig">Figure 1</xref>). Detailed clinical and neuropathological scores were available for each cohort and were used in downstream analyses (<xref rid="SD1" ref-type="supplementary-material">Table S1</xref>). As a validation set, we generated quantitative proteomic data from University of Pennsylvania (UPenn) Brain Bank samples: 384 frontal cortical samples from patients with clinically diagnosed AD, FTD-TDP, PSP-CBD, PD, PD-D, MSA, and ALS (<xref rid="F1" ref-type="fig">Figure 1</xref>). Using a label-free proteomics approach, we were able to identify approximately 65,000 peptides corresponding to approximately 5,000 proteins per sample. To circumvent the problem of missing protein abundance values across different datasets, we allowed for a maximum of 40% missing values. In total, 2,005 quantified proteins overlapped in all five datasets (prefrontal cortex for BLSA, ACT, MSBB, and Banner; temporal cortex for Mayo) and were used for our conservative downstream analysis.</p><sec id="S3"><title>Identification of Robust Disease-Relevant Protein Co-expression Signature</title><p id="P10">To find robust co-expression changes irrespective of brain banks and cortical regions, we employed a consensus-weighted gene co-expression network analysis (cWGCNA) across cohorts from the BLSA, ACT, MSBB, Banner, and Mayo brain banks (<xref rid="F2" ref-type="fig">Figures 2A</xref> and <xref rid="SD4" ref-type="supplementary-material">S1A</xref>). In contrast to other analytical pipelines used for consensus network analyses (<xref rid="R58" ref-type="bibr">Johnson et al., 2020</xref>), the cWGCNA approach does not require batch regression for consensus module generation. We identified 10 consensus modules (labeled C1&#x02013;C10) representing all four major brain cell types: neurons (C1 and C2 modules), microglia/endothelial cells (C10 module), astrocytes (C8 module), and oligodendrocytes (C5 module) (<xref rid="F2" ref-type="fig">Figure 2B</xref>; <xref rid="SD2" ref-type="supplementary-material">Table S2</xref>). We identified two modules (C8 and C10) that were significantly associated with AD diagnosis (p &#x0003c; 0.05) in all five datasets, one module (C1) that was significantly correlated with diagnosis in four datasets, and three additional modules (C2, C3, and C4) that were significantly correlated with diagnosis (p &#x0003c; 0.05) in at least three of the five datasets (see <xref rid="S17" ref-type="sec">Method Details</xref>) for a total of six AD-associated modules. Four consensus modules (C3, C4, C8, and C10) were upregulated in AD compared to controls, and two consensus modules (C1 and C2) were downregulated in AD (<xref rid="F2" ref-type="fig">Figure 2B</xref>).</p><p id="P11">We leveraged three large cohorts of asymptomatic AD cases, where cognition is not affected but where subjects have sufficient neurofibrillary tangles and plaques for a pathological diagnosis (<xref rid="R54" ref-type="bibr">Hyman et al., 2012</xref>), providing a glimpse into early stages of the disease. We defined early AD molecular alterations as changes observed in AsymAD and AD, and late AD molecular alterations were defined as changes only seen in AD. Interestingly, one neuronal module (C1) was downregulated, and two glial modules (C8 and C10) were upregulated early. The modules altered late in disease course were not glial, but instead represented GABAergic neurons, mitogen-activated protein kinase (MAPK) signaling, and RNA splicing (C2, C3, and C4; <xref rid="F2" ref-type="fig">Figure 2B</xref>). <xref rid="SD4" ref-type="supplementary-material">Table S3</xref> summarizes characteristics of early and late modules associated with AD and their association with other neurodegenerative diseases. We also constructed an interactive graphical interface to allow exploration of individual proteins and their network relationships (<ext-link ext-link-type="uri" xlink:href="https://labs.dgsom.ucla.edu/geschwind/files/view/html/ADpNET.html">https://labs.dgsom.ucla.edu/geschwind/files/view/html/ADpNET.html</ext-link>).</p></sec><sec id="S4"><title>Identification of Early Changes in the AD Proteome</title><p id="P12">To identify potential drivers of disease pathology, we focused our attention on modules significantly correlated with AsymAD cases, representing the earliest disease phase. This highlighted module C1 (<xref rid="F3" ref-type="fig">Figures 3A</xref>&#x02013;<xref rid="F3" ref-type="fig">3G</xref> and <xref rid="SD4" ref-type="supplementary-material">S1B</xref>&#x02013;<xref rid="SD4" ref-type="supplementary-material">S1Q</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>) and the C8 and C10 modules, which were upregulated in AsymAD and AD cases (<xref rid="F3" ref-type="fig">Figures 3H</xref>&#x02013;<xref rid="F3" ref-type="fig">3W</xref> and <xref rid="SD4" ref-type="supplementary-material">S2</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>). C1 represented genes highly expressed in neurons (hypergeometric test; p = 1.0e&#x02013;23) and was enriched for synaptic processes, consistent with pre- and post-synaptic vesicle hub proteins such as HOMER1, DLG4, and SYT1 (<xref rid="F3" ref-type="fig">Figure 3A</xref>). The hub gene SYT1, which mediates synaptic vesicle release, is reduced in human AD brain and has been shown to promote A&#x003b2; generation (<xref rid="R37" ref-type="bibr">Gautam et al., 2015</xref>; <xref rid="R90" ref-type="bibr">&#x000d6;hrfelt et al., 2016</xref>; <xref rid="R123" ref-type="bibr">Yoo et al., 2001</xref>).</p><p id="P13">In contrast, C8 represented genes highly expressed in astrocytes (hypergeometric test; p = 8.9e&#x02013;7) and was enriched for immune response and cell-cell adhesion genes. One hub of the C8 module, MSN, is an essential protein involved in P2X7 receptor-mediated cleavage of amyloid precursor protein (APP) (<xref rid="R20" ref-type="bibr">Darmellah et al., 2012</xref>). Another hub protein&#x02014;PRDX6, an antioxidant enzyme&#x02014;is upregulated in astrocytes from patients with Lewy body dementia (<xref rid="R98" ref-type="bibr">Power et al., 2002</xref>) (<xref rid="F3" ref-type="fig">Figure 3H</xref>). C10 was enriched in microglial and endothelial markers. One of its hubs, ANXA1, is a central player in the anti-inflammatory and neuroprotective role of microglia and the clearance of A&#x003b2; (<xref rid="R79" ref-type="bibr">McArthur et al., 2010</xref>; <xref rid="R94" ref-type="bibr">Park et al., 2017</xref>; <xref rid="R103" ref-type="bibr">Ries et al., 2016</xref>). Another hub, CLIC1, is a chloride channel expressed in microglia involved in mediating A&#x003b2; neurotoxicity (<xref rid="R83" ref-type="bibr">Milton et al., 2008</xref>; <xref rid="R111" ref-type="bibr">Skaper et al., 2013</xref>) (<xref rid="F3" ref-type="fig">Figure 3P</xref>). We performed western blotting to validate that several C8 and C10 hub proteins (PADI2, GJA1, PLCD1, and HEPACAM) were increased in AD (<xref rid="SD4" ref-type="supplementary-material">Figure S3</xref>). This analysis clearly demonstrates that neuronal/synaptic gene downregulation and astroglial and microglial upregulation are consistent, early components of AD, consistent with previous analyses (<xref rid="R108" ref-type="bibr">Seyfried et al., 2017</xref>).</p><p id="P14">To identify which, if any, of these molecular traits were related to disease progression, we assessed their relationship to clinical-pathological variables. The C1 module eigenprotein was negatively correlated with amyloid plaques, Consortium to Establish a Registry for Alzheimer&#x02019;s Disease (CERAD) score (<xref rid="R84" ref-type="bibr">Mirra et al., 1991</xref>) (BLSA data, &#x003c1; = &#x02212;0.40, p = 1.0e&#x02013;4) and neurofibrillary tangles, and Braak score (<xref rid="R10" ref-type="bibr">Braak and Braak, 1991</xref>) (BLSA data, &#x003c1; = &#x02212;0.45, p = 9.7e&#x02013;6) across cases and controls (<xref rid="F3" ref-type="fig">Figures 3C</xref> and <xref rid="F3" ref-type="fig">3D</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>). In contrast, the C8 module eigen-protein was positively correlated with CERAD score (ACT data, &#x003c1; = 0.52, p = 2.9e&#x02013;5) and Braak score (ACT data, &#x003c1; = 0.52, p = 2.9e&#x02013;5) and anti-correlated with cognitive status (Cognitive Abilities Screening Instrument [CASI] score; <xref rid="R116" ref-type="bibr">Teng et al., 1994</xref>) (ACT data, &#x003c1; = &#x02212;0.55, p = 7.7e&#x02013;6) (<xref rid="F3" ref-type="fig">Figures 3J</xref>&#x02013;<xref rid="F3" ref-type="fig">3L</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>). A similar pattern was observed for the C10 module (<xref rid="F3" ref-type="fig">Figures 3R</xref>&#x02013;<xref rid="F3" ref-type="fig">3T</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>) and similar trends were observed with the other study cohorts (<xref rid="SD4" ref-type="supplementary-material">Figures S1B</xref>&#x02013;<xref rid="SD4" ref-type="supplementary-material">S1Q</xref> and <xref rid="SD4" ref-type="supplementary-material">S2</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>).</p><p id="P15">We next analyzed an independent dataset (UPenn; see <xref rid="S17" ref-type="sec">Method Details</xref>), which also contained seven non-AD diseases for comparison. The observed trends for the C1, C8, and C10 modules, including correlations with CERAD and Braak scores, were recapitulated in AD (<xref rid="F3" ref-type="fig">Figures 3E</xref>&#x02013;<xref rid="F3" ref-type="fig">3G</xref>, <xref rid="F3" ref-type="fig">3M</xref>&#x02013;<xref rid="F3" ref-type="fig">3O</xref>, and <xref rid="F3" ref-type="fig">3U</xref>&#x02013;<xref rid="F3" ref-type="fig">3W</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>). Notably, these early disease-associated modules were significantly altered only in conditions with prominent dementia (C1: FTD-TDP, PSP-CBD, and PD-D) (<xref rid="F3" ref-type="fig">Figure 3E</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>) (C8: FTD-TDP, PSP-CBD, and PD-D) (<xref rid="F3" ref-type="fig">Figure 3M</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>) (C10: FTD-TDP and PSP-CBD) (<xref rid="F3" ref-type="fig">Figure 3U</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>), but not in other neurodegenerative diseases where dementia is not a primary feature (MSA, ALS, and PD). We validated our findings using data from a second independent study (Emory; <xref rid="R97" ref-type="bibr">Ping et al., 2018</xref>) that used multiplex isobaric tandem mass tags (TMTs) and offline fractionation for protein quantification that identified more than 11,000 proteins (<xref rid="SD4" ref-type="supplementary-material">Figures S2</xref> and <xref rid="SD4" ref-type="supplementary-material">S3</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>). We also note that all prefrontal proteomic modules (F1&#x02013;F10) have significant module preservation in the temporal cortex (<italic>Z<sub>summary</sub></italic> module preservation range 2.5 to 18.5; <xref rid="SD4" ref-type="supplementary-material">Table S5</xref>).</p></sec><sec id="S5"><title>Identification of Late Changes in the AD Proteome</title><p id="P16">We next evaluated proteomic changes occurring in cases representing the later, symptomatic phases of AD, identifying one downregulated (C2) and two upregulated (C3 and C4) modules in AD, but not changing in AsymAD. C2, which consisted of mitochondrial electron transport chain subunits and ATPase subunits (<xref rid="F4" ref-type="fig">Figures 4A</xref>&#x02013;<xref rid="F4" ref-type="fig">4G</xref>), was decreased with progression of disease as measured by CERAD and Braak scores (<xref rid="F4" ref-type="fig">Figures 4B</xref>&#x02013;<xref rid="F4" ref-type="fig">4D</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>) and was enriched in GABAergic markers (<xref rid="R104" ref-type="bibr">Romanov et al., 2017</xref>). Upregulated module C3 (<xref rid="F4" ref-type="fig">Figures 4H</xref>&#x02013;<xref rid="F4" ref-type="fig">4O</xref>), which was positively correlated with CERAD and Braak scores and anti-correlated with CASI scores (<xref rid="F4" ref-type="fig">Figures 4I</xref>&#x02013;<xref rid="F4" ref-type="fig">4L</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>), was enriched with genes involved in MAPK signaling. Module C4 (<xref rid="F4" ref-type="fig">Figures 4P</xref>&#x02013;<xref rid="F4" ref-type="fig">4V</xref>) was also positively correlated with CERAD and Braak scores (<xref rid="F4" ref-type="fig">Figures 4Q</xref>&#x02013;<xref rid="F4" ref-type="fig">4S</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>), but was enriched for genes involved in mRNA splicing. Similar trends were observed for these modules with the other study cohorts (<xref rid="F4" ref-type="fig">Figures 4E</xref>&#x02013;<xref rid="F4" ref-type="fig">4G</xref>, <xref rid="F4" ref-type="fig">4M</xref>&#x02013;<xref rid="F4" ref-type="fig">4O</xref>, <xref rid="F4" ref-type="fig">4T</xref>&#x02013;<xref rid="F4" ref-type="fig">4V</xref>, <xref rid="SD4" ref-type="supplementary-material">S4</xref>, and <xref rid="SD4" ref-type="supplementary-material">S5</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S4</xref>).</p></sec><sec id="S6"><title>Comparison of the AD Proteome and Transcriptome</title><p id="P17">We reasoned that it would be important to understand how transcriptomic data were reflected at the level of proteomics collected from the same individuals in the same brain region, especially since little such comparative data are available in dementia. We leveraged 80 PSP, 80 AD, and 28 control cortical samples in the Mayo cohort in which proteomics and RNA-seq data were available from the same samples. We observed that for genes differentially expressed in PSP compared to AD (false discovery rate [FDR] &#x0003c; 0.1), the PSP-to-AD fold-change at the RNA level was significantly correlated with the fold-change at the protein level (&#x003b2; = 0.58, R<sup>2</sup> = 0.56, p = 8.7e&#x02013;165; <xref rid="F5" ref-type="fig">Figure 5A</xref>). This suggests that slightly more than half of the variance in protein expression reflects gene expression, but an almost equivalent proportion of the signal is post-transcriptional, strongly supporting the utility of protein profiling and the complementarity of these two datasets.</p><p id="P18">To delineate the conservation of biological processes at the proteome and transcriptome levels, we created separate co-expression networks for RNA (labeled T1&#x02013;T21 modules from 11,140 transcripts) and protein (labeled P1&#x02013;P15 modules from 3,849 proteins; <xref rid="SD4" ref-type="supplementary-material">Figure S6A</xref>) using only the Mayo cohort. As expected, all consensus proteomic modules overlapped with at least one &#x0201c;Mayo only&#x0201d; proteomic module (<xref rid="F5" ref-type="fig">Figures 5B</xref> and <xref rid="SD4" ref-type="supplementary-material">S6B</xref>). Also per expectations, proteomic modules overall had lower connectivity than did the transcriptomic modules (<xref rid="F5" ref-type="fig">Figure 5C</xref>; <xref rid="SD4" ref-type="supplementary-material">Table S6</xref>) and lower clustering coefficients (<xref rid="SD4" ref-type="supplementary-material">Table S6</xref>; p value range &#x0003c; 2.2e&#x02013;16 to 7.2e&#x02013;4), consistent with lower number of proteins compared with transcripts and subsequent higher connectivity within transcriptomic modules. The glial consensus modules upregulated early in AD, C8 (astrocyte) and C10 (microglia/endothelial cells), and the late upregulated module C4 (mRNA splicing) overlapped with the Mayo protein P3 module (C4-P3 hypergeometric overlap odds ratio (OR) = 7; C8-P3 hypergeometric overlap OR = 25; C10-P3 hypergeometric overlap OR = 33; <xref rid="SD4" ref-type="supplementary-material">Figure S6B</xref>). The Mayo P3 module was enriched for mRNA splicing and for genes that were markers for both astrocyte and microglial cell types, and it overlapped with multiple Mayo transcriptomic modules that were enriched for the same pathways and cell types: T3, T8, T9, T18, and T21 (<xref rid="F5" ref-type="fig">Figures 5B</xref> and <xref rid="SD4" ref-type="supplementary-material">S6C</xref>; hypergeometric overlap, OR ranges 5&#x02013;12). The consensus module downregulated in AD (C1) overlapped with the Mayo protein module P4 (OR = 11) and T1 transcriptomic module (OR = 4) (<xref rid="F5" ref-type="fig">Figures 5B</xref> and <xref rid="SD4" ref-type="supplementary-material">S6C</xref>).</p><p id="P19">We next identified hub genes associated with disease altered at both the RNA and protein levels, which we reasoned would be worth highlighting as some may be candidate high-confidence therapeutic targets. Upregulated genes associated with processes associated with AD include HNRNPF (modules C4, P3, and T9; <xref rid="F5" ref-type="fig">Figure 5B</xref>) (<xref rid="R39" ref-type="bibr">Geuens et al., 2016</xref>; <xref rid="R101" ref-type="bibr">Raj et al., 2018</xref>), MSN (modules C8, P3, and T21; <xref rid="F5" ref-type="fig">Figure 5B</xref>) (<xref rid="R20" ref-type="bibr">Darmellah et al., 2012</xref>), GFAP (modules C8, P3, and T18; <xref rid="F5" ref-type="fig">Figure 5B</xref>) (<xref rid="R27" ref-type="bibr">Dzamba et al., 2016</xref>; <xref rid="R28" ref-type="bibr">Efthymiou and Goate, 2017</xref>), DDAH2 (modules C8, P3, and T3; <xref rid="F5" ref-type="fig">Figure 5B</xref>), GSN (modules C8, P3, and T9; <xref rid="F5" ref-type="fig">Figure 5B</xref>), VIM (modules C10, P3, and T21; <xref rid="F5" ref-type="fig">Figure 5B</xref>), and AHNAK (modules C10, P3, and T3; <xref rid="F5" ref-type="fig">Figure 5B</xref>) (<xref rid="R110" ref-type="bibr">Sims et al., 2017</xref>). Those upregulated included synaptic proteins like SYT1 and STX1A, both involved in vesicle trafficking (<xref rid="R37" ref-type="bibr">Gautam et al., 2015</xref>; <xref rid="R112" ref-type="bibr">Smith et al., 2000</xref>), and ATP6V0D, involved in lysosomal acidification and linked to AD pathogenesis (<xref rid="R15" ref-type="bibr">Colacurcio and Nixon, 2016</xref>).</p></sec><sec id="S7"><title>Non-overlapping Proteomic and Transcriptomic Modules</title><p id="P20">The electronic transport chain (C2) and MAPK (C3) late proteomic modules did not overlap with the transcriptomic modules, suggesting exclusive disease signatures identified via co-expression proteomic analyses. We found that a large percentage of genes from these non-overlapping proteomic modules were not assigned to any transcriptomic modules, indicating that the RNA of these unassigned genes, while expressed at moderate levels, did not have strong co-expression with genes in any transcriptomic module. Thus, we reasoned that these modules likely reflect post-transcriptional regulation, as they were not captured in the transcriptome (<xref rid="R49" ref-type="bibr">Hicke, 2001</xref>; <xref rid="R130" ref-type="bibr">Zhao et al., 2017</xref>). Consistent with this, we observe that the PSP-to-AD RNA-protein fold-change correlation was positive (&#x003b2; = 0.58) in modules captured in both RNA and protein, whereas the correlations were lower or negative for non-overlapping proteomic modules (&#x003b2; = &#x02212;0.41 for C2 and &#x003b2; = 0.30 for C3). Non-overlapping proteomic modules represented genes with significantly lower RNA-to-protein correlation than average, consistent with data showing that MAPK pathway (C3) proteins show strong post-transcriptional (<xref rid="R114" ref-type="bibr">Sugiura et al., 2011</xref>; <xref rid="R121" ref-type="bibr">Whelan et al., 2012</xref>) and post-translational regulation (<xref rid="R75" ref-type="bibr">Lin et al., 2003</xref>).</p></sec><sec id="S8"><title>Genetic Risk Is Enriched in Specific Proteomic Modules</title><p id="P21">The observed proteomic changes may be a cause or consequence of the disease. We next integrated genetic risk and genome-wide association studies (GWASs) to understand each module&#x02019;s relationship to potential causal mechanisms (<xref rid="R35" ref-type="bibr">Gandal et al., 2018a</xref>; <xref rid="R93" ref-type="bibr">Parikshak et al., 2016</xref>). First, all early and late disease-associated modules showed significant correlation with <italic>APOE</italic> &#x003b5;4 allele dosage (0, 1, or 2) in the expected direction. For example, modules upregulated in brains from patients diagnosed with AD (C8, C10, C3, and C4) showed positive correlation with APOE (Banner data, C8: &#x003c1; = 0.27, p = 1.7e&#x02013;4; Banner data C10: &#x003c1; = 0.22, p = 2.4e&#x02013;3; Banner data C3: &#x003c1; = 0.2, p = 5.8e&#x02013;3; Mayo C4: &#x003c1; = 0.21, p = 3.1e&#x02013;3) and the downregulated modules (C1 and C2) showed negative correlation with APOE (Banner data, C1: &#x003c1; = &#x02212;0.19, p = 8.8e&#x02013;3; Banner data, C2: &#x003c1; = &#x02212;0.25, p = 5.2e&#x02013;4), consistent with expectations (<xref rid="SD3" ref-type="supplementary-material">Table S4</xref>). Next, we used summary data from AD GWAS as input for Multi-marker Analysis of GenoMic Annotation (MAGMA) (<xref rid="R23" ref-type="bibr">de Leeuw et al., 2015</xref>), finding that common variants from AD GWAS (<xref rid="R67" ref-type="bibr">Lambert et al., 2013</xref>) were significantly enriched in genes within the consensus C8 (astrocyte) and C10 (microglia) modules (<xref rid="F6" ref-type="fig">Figure 6A</xref>), in addition to the overlapping Mayo proteomics P3 module (<xref rid="F6" ref-type="fig">Figure 6B</xref>) and Mayo transcriptomics T3 and T8 modules (<xref rid="F6" ref-type="fig">Figure 6C</xref>). This is consistent with previous reports of AD candidate gene enrichment in glial modules (<xref rid="R58" ref-type="bibr">Johnson et al., 2020</xref>; <xref rid="R108" ref-type="bibr">Seyfried et al., 2017</xref>; <xref rid="R127" ref-type="bibr">Zhang et al., 2013</xref>). Combined with the early upregulation of C8 and C10 and their preservation in multiple datasets, this highlights the co-regulated set of genes in C8 and C10 as potential targets for disease modification.</p><p id="P22">In striking contrast, common variants from PSP GWAS (<xref rid="R51" ref-type="bibr">H&#x000f6;glinger et al., 2011</xref>) were significantly enriched in the early neuronal, C1 module (<xref rid="F6" ref-type="fig">Figure 6A</xref>) and the overlapping Mayo proteomics P4 module (<xref rid="F6" ref-type="fig">Figure 6B</xref>) and Mayo transcriptomic, T1, module (<xref rid="F6" ref-type="fig">Figure 6C</xref>). These analyses illustrate two major points: (1) genetic risk enriches in modules with early changes in disease, consistent with the causal role of genetic risk variants; and (2) causal risk variants in these two tauopathies associated with dementia (AD and PSP) differ in terms of the specific biology and cell types that they causally impact (<xref rid="F6" ref-type="fig">Figure 6D</xref>).</p></sec></sec><sec id="S9"><title>DISCUSSION</title><p id="P23">Quantifying changes in the brain proteome provides a direct means of understanding the molecular pathology in proteinopathies such as AD (<xref rid="R6" ref-type="bibr">Arnold et al., 2013</xref>; <xref rid="R33" ref-type="bibr">Forman et al., 2004</xref>; <xref rid="R105" ref-type="bibr">Ross and Poirier, 2004</xref>). Understanding the key drivers in a proteomic network that are enriched for causal genetic risk has direct implications for identifying druggable protein targets for the disease. By combining multiple cohorts of post-mortem human AD brains with label-free proteomics, we detected robust proteomic modules representing early and late changes associated with AD that were conserved in other neurodegenerative dementias and at the transcriptomic level. We found two specific consensus proteomic modules enriched for AD genetic risk and a distinct consensus module associated with PSP genetic risk variants. This analysis provides insights into the pathogenic processes related to AD onset and progression, many of which are conserved across neurodegenerative dementias. Despite these shared aspects of molecular pathology delineated by protein co-expression networks, we find that different dementias do show specificity with regards to enrichment for causal genetic risk, indicative of distinct inception points in these disorders.</p><p id="P24">One of the major challenges in using proteomics approaches is the limited scalability and reproducibility of proteomic studies to identify disease-specific alterations in large cohorts. While previous AD proteomic studies incorporated one or two datasets (<xref rid="R57" ref-type="bibr">Johnson et al., 2018</xref>; <xref rid="R80" ref-type="bibr">McKenzie et al., 2017</xref>; <xref rid="R97" ref-type="bibr">Ping et al., 2018</xref>; <xref rid="R108" ref-type="bibr">Seyfried et al., 2017</xref>; <xref rid="R125" ref-type="bibr">Yu et al., 2018</xref>; <xref rid="R129" ref-type="bibr">Zhang et al., 2018</xref>), we integrated data representing five different cohorts and used a bioinformatics approach to define robust disease-associated proteomic networks. While this work was in revision, a similarly large analysis of proteomic changes in AD using multiple cohorts from AMP-AD was published that highlighted multiple cell-type and molecular pathways that are altered in AD (<xref rid="R58" ref-type="bibr">Johnson et al., 2020</xref>), findings highly concordant with our current analysis. In contrast to Johnson et al., our cWGCNA approach bypassed the need for batch correction, which can lead to the removal or compression of the disease signal (<xref rid="R36" ref-type="bibr">Gandal etal., 2018b</xref>; <xref rid="R115" ref-type="bibr">Swarup et al., 2019</xref>), and we indeed observe larger signals in disease-associated module eigenproteins. Our work is complementary in that different pipelines and analytic approaches are used here, including consensus network analysis and an additional cohort for network construction, indicating that the major findings in both studies are robust to different analytical pipelines.</p><p id="P25">Our study is the largest to comprehensively compare RNA and protein co-expression in dementia. These early neuronal (C1) and glial (C8 and C10) consensus proteomic modules significantly overlapped with transcriptomic modules, suggesting these biological processes are altered at both the RNA and protein levels. Previous AD transcriptomic co-expression analyses also showed upregulation of inflammatory astrocytic and microglial signatures and downregulation of neuronal signatures (<xref rid="R86" ref-type="bibr">Mostafavi et al., 2018</xref>; <xref rid="R108" ref-type="bibr">Seyfried et al., 2017</xref>; <xref rid="R115" ref-type="bibr">Swarup et al., 2019</xref>; <xref rid="R119" ref-type="bibr">Wang et al., 2016</xref>). Our analysis also demonstrated the early disease-associated modules were correlated only with neurodegenerative conditions with dementia (FTD-TDP, PSP-CBD, and PD-D) and not in neurodegenerative diseases where dementia is not a primary feature (MSA, ALS, and PD).</p><p id="P26">Although these data highlight the role of neuronal loss (<xref rid="R10" ref-type="bibr">Braak and Braak, 1991</xref>; <xref rid="R11" ref-type="bibr">Braak et al., 2003</xref>; <xref rid="R21" ref-type="bibr">Davidson et al., 2007</xref>; <xref rid="R24" ref-type="bibr">De Strooper and Karran, 2016</xref>; <xref rid="R26" ref-type="bibr">Dickson et al., 2010</xref>; <xref rid="R46" ref-type="bibr">Hauw et al., 1994</xref>; <xref rid="R78" ref-type="bibr">Mackenzie et al., 2011</xref>) and astrocyte (<xref rid="R42" ref-type="bibr">Gonz&#x000e1;lez-Reyes et al., 2017</xref>; <xref rid="R96" ref-type="bibr">Perez-Nievas and Serrano-Pozo, 2018</xref>; <xref rid="R100" ref-type="bibr">Radford et al., 2015</xref>) and microglial (<xref rid="R8" ref-type="bibr">Bachiller et al., 2018</xref>; <xref rid="R30" ref-type="bibr">Fern&#x000e1;ndez-Botr&#x000e1;n et al., 2011</xref>; <xref rid="R45" ref-type="bibr">Hansen et al., 2018</xref>; <xref rid="R55" ref-type="bibr">Ishizawa and Dickson, 2001</xref>; <xref rid="R88" ref-type="bibr">Navarro et al., 2018</xref>; <xref rid="R100" ref-type="bibr">Radford et al., 2015</xref>) upregulation in the pathogenesis of all of these diseases, their time course and the enrichment of genetic risk in all three early disease-associated modules are consistent with the prediction that causal changes should occur at the earliest points in the disease course. However, the risk for different disorders was differentially distributed. Common partitioned heritability for PSP identified in GWASs was significantly enriched in the early C1 neuronal module, indicating that neuronal dysfunction is the primary causal driver in this disease. Synaptic loss is a common theme across all neurodegenerative diseases, but genetic enrichment in specific synaptic modules is not observed universally. In contrast, AD genetic signal from GWASs was enriched in the C8, astrocytic, and C10 microglia modules, which supports the emerging consensus of a glial-immune etiology in AD (<xref rid="R28" ref-type="bibr">Efthymiou and Goate, 2017</xref>; <xref rid="R47" ref-type="bibr">Heckmann et al., 2019</xref>; <xref rid="R48" ref-type="bibr">Heneka et al., 2015</xref>; <xref rid="R52" ref-type="bibr">Hong et al., 2016</xref>; <xref rid="R56" ref-type="bibr">Ising et al., 2019</xref>; <xref rid="R62" ref-type="bibr">Keren-Shaul et al., 2017</xref>; <xref rid="R74" ref-type="bibr">Liddelow et al., 2017</xref>; <xref rid="R89" ref-type="bibr">Nott et al., 2019</xref>; <xref rid="R120" ref-type="bibr">Wang et al., 2015</xref>). While some neuronal changes occur early in AD, as evidenced by the changes in C1, the causal elements reside in genes associated with glial cells.</p><p id="P27">As proteins represent druggable targets (Agora. Accelerating Medicines Partnership in Alzheimer&#x02019;s Disease; <xref rid="R43" ref-type="bibr">Griffith et al., 2013</xref>; <xref rid="R53" ref-type="bibr">Hopkins and Groom, 2002</xref>; <xref rid="R91" ref-type="bibr">Oprea et al., 2018</xref>), we further examined the hubs of the C8 and C10 modules, which were early AD associated, had transcriptomic co-expression concordance, converged with other neurodegenerative dementias, and had AD causal genetic enrichment. For example, both GSN and MSN are preserved C8 hub genes linked to AD pathogenic mechanisms (<xref rid="R20" ref-type="bibr">Darmellah et al., 2012</xref>; <xref rid="R58" ref-type="bibr">Johnson et al., 2020</xref>; <xref rid="R108" ref-type="bibr">Seyfried et al., 2017</xref>). MSN and GSN are both considered druggable based on the Drug Gene Interaction database (Agora. Accelerating Medicines Partnership in Alzheimer&#x02019;s Disease; <xref rid="R43" ref-type="bibr">Griffith et al., 2013</xref>). Other preserved C8 hub genes such as DDAH2 have not yet been linked to AD pathogenesis but are potentially druggable. In module C10, two hub genes, ANXA1 and GJA, have been previously associated with AD mechanisms (<xref rid="R60" ref-type="bibr">Kajiwara et al., 2018</xref>; <xref rid="R79" ref-type="bibr">McArthur et al., 2010</xref>).</p><p id="P28">In addition to these early disease-associated modules, we also identified late AD-associated modules (C2, C3, and C4), which may represent biological processes associated with chronic disease progression. When comparing late AD-associated consensus proteomic modules (C2, C3, and C4) to transcriptomic co-expression modules, the mRNA splicing C4 module was preserved in the transcriptomic network. Previous proteomic studies have identified RNA splicing (<xref rid="R41" ref-type="bibr">Golde et al., 1990</xref>; <xref rid="R77" ref-type="bibr">Love et al., 2015</xref>; <xref rid="R101" ref-type="bibr">Raj et al., 2018</xref>) signatures downregulated later in AD progression as well.</p><p id="P29">Our analyses did yield modules not observed in previous transcriptomic studies. Both C2 and C3, representing electron transport and MAPK pathways, respectively, did not overlap with transcriptomic modules. Accordingly, genes within these modules show lower protein-RNA correlation compared with the average observed across the genome. As late biological processes, these may be adaptive responses to AD pathology or propagate disease progression after AD pathology is established. Mitochondrial modules were associated with AD using transcriptomics and proteomics in previous studies (<xref rid="R57" ref-type="bibr">Johnson et al., 2018</xref>; <xref rid="R64" ref-type="bibr">Kim and Choi, 2015</xref>; <xref rid="R86" ref-type="bibr">Mostafavi et al., 2018</xref>; <xref rid="R87" ref-type="bibr">Munoz and Ammit, 2010</xref>; <xref rid="R97" ref-type="bibr">Ping et al., 2018</xref>; <xref rid="R109" ref-type="bibr">Shih et al., 2015</xref>). The mitochondrial C2 module was the only module shared across all neurodegenerative diseases, including those with and without dementia (AD, FTD TDP, PSP-CBD, PD-D, MSA, ALS, and PD). This highlights that dysfunctional energy metabolism, possibly due to impaired mitochondria trafficking or oxidative phosphorylation, is likely dysregulated in all of these neurodegenerative disorders at late stages (<xref rid="R12" ref-type="bibr">Briston and Hicks, 2018</xref>). C2 is not enriched in genetic risk and is dysregulated late in disease, suggesting that while it is shared across neurodegenerative disorders, it does not drive early disease pathophysiology.</p><p id="P30">Dysregulation of MAPK signaling was identified in a previous smaller, proteomic study (<xref rid="R108" ref-type="bibr">Seyfried et al., 2017</xref>) but has not been clearly identified in transcriptomic studies. MAPK signaling is implicated in many pathways dysregulated in dementia, including immune (<xref rid="R59" ref-type="bibr">Jones and Kounatidis, 2017</xref>; <xref rid="R73" ref-type="bibr">Lee and Kim, 2017</xref>; <xref rid="R131" ref-type="bibr">Zhu et al., 2002</xref>), oxidative stress (<xref rid="R87" ref-type="bibr">Munoz and Ammit, 2010</xref>; <xref rid="R109" ref-type="bibr">Shih et al., 2015</xref>), and tau hyperphosphorylation (<xref rid="R44" ref-type="bibr">Guise et al., 2001</xref>; <xref rid="R63" ref-type="bibr">Kim and Choi, 2010</xref>; <xref rid="R118" ref-type="bibr">Wang and Liu, 2008</xref>). The potential contribution of PEA-15, one of the C3 modules hubs, to AD pathogenesis has not been studied. Thus, in addition to identifying molecular disease processes previously associated with AD, proteomic co-expression analysis can identify less-established mechanisms.</p><p id="P31">Our consensus proteomic co-expression approach did not identify all processes associated with AD in previous proteomic and transcriptomic co-expression analyses (e.g., decreased cytoskeletal and microtubule signatures in AD) (<xref rid="R4" ref-type="bibr">Andreev et al., 2012</xref>; <xref rid="R108" ref-type="bibr">Seyfried et al., 2017</xref>; <xref rid="R129" ref-type="bibr">Zhang et al., 2018</xref>). Our study&#x02019;s microtubule C5 module was not consistently downregulated in AD across cohorts. Our consensus proteomic modules also did not include cell cycle, chromatin modification, glucuronosyl-transferase, or axon guidance modules that were identified in several transcriptomic studies (<xref rid="R86" ref-type="bibr">Mostafavi et al., 2018</xref>; <xref rid="R119" ref-type="bibr">Wang et al., 2016</xref>; <xref rid="R127" ref-type="bibr">Zhang et al., 2013</xref>). This is perhaps, in part, a limitation of proteomic studies, where less soluble or very large membrane-associated proteins are more difficult to detect, and the conservative consensus approach, again supporting the complementarity of multi-omics approaches and the value of measuring distinct molecular species. Overall, our multi-omics, multi-cohort approach provides insights into early and late changes in AD that are shared with other neurodegenerative dementias but show disease specificity for genetic risk. Those modules with consistent molecular alterations at the genetic, transcriptomic, and proteomic levels are ripe for future investigation as drug targets.</p></sec><sec id="S10"><title>STAR&#x02605;METHODS</title><sec id="S11"><title>RESOURCE AVAILABILITY</title><sec id="S12"><title>Lead Contact</title><p id="P32">Further information and requests for resources and reagents should be directed to the Lead Contact, Daniel H. Geschwind.</p></sec><sec id="S13"><title>Material Availability</title><p id="P33">This study did not generate new unique reagents. Further information and requests for resources and reagents should be directed to the Lead Contact, Daniel H. Geschwind.</p></sec><sec sec-type="data-availability" id="S14"><title>Data and Code Availability</title><p id="P34">All the proteomics data are available here: <ext-link ext-link-type="uri" xlink:href="https://adknowledgeportal.synapse.org/Explore/Projects?Grant%20Number=U01AG046161">https://adknowledgeportal.synapse.org/Explore/Projects?Grant%20Number=U01AG046161</ext-link>. Links to data for each study can be found in the <xref rid="T1" ref-type="table">Key Resources Table</xref>. The accession number for the ACT data reported in this paper is <ext-link ext-link-type="uri" xlink:href="https://www.synapse.org/">https://www.synapse.org/</ext-link> Synapse ID:syn5759376. The accession number for the MSBB data reported in this paper is <ext-link ext-link-type="uri" xlink:href="https://www.synapse.org/">https://www.synapse.org/</ext-link> Synapse ID:syn3159438. The accession number for the Banner data reported in this paper is <ext-link ext-link-type="uri" xlink:href="https://www.synapse.org/">https://www.synapse.org/</ext-link> Synapse ID:syn7170616. The accession number for the Mayo data reported in this paper is <ext-link ext-link-type="uri" xlink:href="https://www.synapse.org/">https://www.synapse.org/</ext-link> Synapse ID:syn5550404. The accession number for the UPenn data reported in this paper is <ext-link ext-link-type="uri" xlink:href="https://adknowledgeportal.synapse.org">https://adknowledgeportal.synapse.org</ext-link> Synapse ID:syn21411742.</p><p id="P35">Code is available on GitHub: <ext-link ext-link-type="uri" xlink:href="https://github.com/dhglab/Identification-of-conserved-proteomic-networks-in-neurodegenerative-dementia">https://github.com/dhglab/Identification-of-conserved-proteomic-networks-in-neurodegenerative-dementia</ext-link></p></sec></sec><sec id="S15"><title>EXPERIMENTAL MODEL AND SUBJECT DETAILS</title><sec id="S16"><title>Human Samples</title><p id="P36">Postmortem human brain tissues were obtained from the Baltimore Longitudinal Study of Aging (BLSA) at Johns Hopkins University, Adult Changes of Thought (ACT) at the University of Washington and Group Health Cooperative of Puget Sound, Mount Sinai Brain Bank (MSBB) at Mount Sinai University, Banner Sun Health Research Institute (Banner), Mayo Clinic Brain Bank (Mayo) at the Mayo Clinic in Jacksonville, Florida, University of Pennsylvania Brain Bank (UPenn), and Emory University (Emory). All human samples were obtained under their respective institutional review board. For details about sample-level metadata including diagnosis, gender, neuropathological criteria, etc. please see <xref rid="SD1" ref-type="supplementary-material">Table S1</xref>. The BLSA samples consisted of 97 samples from the dorsolateral prefrontal cortex (BA9 area) and precuneus (parietal cortex, BA7) representing 15 controls, 15 AsymAD and 20 AD cases (<xref rid="R108" ref-type="bibr">Seyfried et al., 2017</xref>). The BLSA precuneus region was not used in our analyses. The ACT samples consisted of 65 samples from 12 controls, 14 AsymAD and 39 AD cases from prefrontal cortex area. The MSBB consisted of 251 prefrontal cortex samples from 78 controls, 28 AD possible, 13 AD probable and 132 AD definite cases based on clinical dementia rating (CDR) scores (<xref rid="R85" ref-type="bibr">Morris, 1993</xref>). The Banner samples were from prefrontal cortex of 30 controls, 28 mild cognitive impairment, 33 AsymAD and 98 confirmed AD cases. The Mayo samples were from temporal cortex consisting of 28 controls, 84 AD, and 84 PSP cases. The UPenn samples were from prefrontal cortex consisting of 43 controls, 42 AD, 58 ALS, 29 FTD-TDP, 22 MSA, 33 PD, 58 PD-dementia, and 48 PSP-CBD. Emory samples were previously published (<xref rid="R97" ref-type="bibr">Ping et al., 2018</xref>; <xref rid="R108" ref-type="bibr">Seyfried et al., 2017</xref>). This study was performed under the auspices of the UCLA Office of Human Research Protection, which determined that it was exempt because samples were anonymous pathological specimens (IRB# 15-001397).</p></sec></sec><sec id="S17"><title>METHOD DETAILS</title><sec id="S18"><title>Quantitative Proteomics</title><p id="P37">Label-free quantitative proteomics were performed at the Emory Proteomics Core, Emory University, USA. Detailed methods were published elsewhere (<xref rid="R108" ref-type="bibr">Seyfried et al., 2017</xref>). The label free quantitation (LFQ) algorithm in MaxQuant (<xref rid="R17" ref-type="bibr">Cox and Mann, 2008</xref>) was used for protein quantitation. The quantitation method only considered razor and unique peptides for protein level quantitation. The LFQ intensities were log2 transformed for downstream analyses.</p></sec><sec id="S19"><title>Covariate correction</title><p id="P38">Protein LFQ (proteomics) and normalized FPKM values (RNA-seq) were assessed for effects from biological covariates (diagnosis, age, gender) and technical variables (batch, brain bank, etc.). We used a linear regression model accounting for biological and technical covariates depending upon the cohort to be analyzed. The final model used was implemented in R version 3.6.1 (<xref rid="R99" ref-type="bibr">R Core Team, 2019</xref>) as follows:
<disp-formula id="FD1"><mml:math display="block" id="M1"><mml:mrow><mml:mi>lm</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mtext>expression</mml:mtext><mml:mi>~</mml:mi></mml:msup><mml:mtext>diagnosis</mml:mtext><mml:mo>+</mml:mo><mml:mtext>age</mml:mtext><mml:mo>+</mml:mo><mml:mtext>gender</mml:mtext><mml:mo>+</mml:mo><mml:mtext>batch</mml:mtext><mml:mo>+</mml:mo><mml:mtext>brain.bank.batch</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></disp-formula></p></sec><sec id="S20"><title>Consensus WGCNA</title><p id="P39">Consensus weighted co-expression network analysis (cWGCNA) was performed in R (<xref rid="R99" ref-type="bibr">R Core Team, 2019</xref>) using WGCNA package (<xref rid="R70" ref-type="bibr">Langfelder and Horvath, 2008</xref>). To identify consensus proteomics modules across different brain banks, we employed a signed cWGCNA approach by calculating component-wise values for topological overlap for individual brain banks. Biweighted mid-correlations were calculated for all pairs of genes, and then a signed similarity matrix was created. In the signed network, the similarity between genes reflects the sign of the correlation of their expression profiles. The signed similarity matrix was then raised to power &#x003b2; to emphasize strong correlations and reduce the emphasis of weak correlations on an exponential scale. The resulting adjacency matrix was then transformed into a topological overlap matrix (TOM). The consensus TOM (cTOM) was calculated by taking the component-wise minimum of TOMs in each dataset. Using 1 &#x02013; cTOM as the distance measure, genes were hierarchically clustered (<xref rid="R93" ref-type="bibr">Parikshak et al., 2016</xref>). Module assignments were determined using a dynamic tree-cutting algorithm (cutreeHybrid, using the default parameters except deepSplit = 4, cutHeight = 0.999, minModuleSize = 20, dthresh = 0.07 and pamStage = FALSE). Network visualization was performed with the igraph package in R (<xref rid="R18" ref-type="bibr">Csardi and Nepusz, 2006</xref>).</p><p id="P40">Module eigenproteins were calculated as the first principal component of the coexpressed genes in the module (<xref rid="R69" ref-type="bibr">Langfelder and Horvath, 2007</xref>; <xref rid="R126" ref-type="bibr">Zhang and Horvath, 2005</xref>). The eigengene-based connectivity (kME) was used to represent the strength of a gene&#x02019;s correlation with other gene module members. It is defined as the correlation between a gene&#x02019;s expression and the module eigengene (<xref rid="R69" ref-type="bibr">Langfelder and Horvath, 2007</xref>; <xref rid="R126" ref-type="bibr">Zhang and Horvath, 2005</xref>). Hub genes of a module were considered genes with high kME.</p></sec></sec><sec id="S21"><title>QUANTIFICATION AND STATISTICAL ANALYSIS</title><sec id="S22"><title>Cell-type and Gene-ontology enrichment</title><p id="P41">For gene-set enrichment analysis of cell type (<xref rid="R82" ref-type="bibr">Miller et al., 2008</xref>; <xref rid="R104" ref-type="bibr">Romanov et al., 2017</xref>; <xref rid="R128" ref-type="bibr">Zhang et al., 2016</xref>) and gene ontology (<xref rid="R7" ref-type="bibr">Ashburner et al., 2000</xref>; <xref rid="R38" ref-type="bibr">Gene Ontology Consortium, 2019</xref>; <xref rid="R124" ref-type="bibr">Yu et al., 2012</xref>) we use the hypergeometric test, which is equivalent to a onesided Fisher&#x02019;s exact test, to evaluate whether a gene set is enriched over background, providing a p value and enrichment value for gene set enrichment (<xref rid="R93" ref-type="bibr">Parikshak et al., 2016</xref>). An assumption with such a test is that the background set is similar to the gene set considered for enrichment in all factors other than pathway membership.</p></sec><sec id="S23"><title>Module Eigenprotein Association with Disease</title><p id="P42">We determined if a module eigenprotein was significantly different from disease diagnosis (AD or AsymAD) versus control using the Wilcoxon rank sum test (<xref rid="R122" ref-type="bibr">Wilcoxon, 1945</xref>). A module was considered as late if it was significantly associated with AD compared to control in at least three of the five cohorts. A module was considered early if it was significantly associated with AsymAD and AD compared to control in at least one of three cohorts with AsymAD (Banner, ACT, BLSA) and significantly associated with AD in at least three of the five cohorts.</p><p id="P43">For the Mayo only proteomic module analyses, we compared AD to control and AD to PSP given the lower number of control available (28) compared to AD (84) and PSP (84). Comparing AD to control had reduced power versus comparing AD to PSP. To determine if a consensus proteomic module was associated with AD in the Mayo cohort, we only compared AD to control in order to be consistent with the above late module criteria in other cohorts, which also compared AD to controls.</p><p id="P44">Module eigenproteins were correlated with clinical score (CASI) and neuropathological scores (CERAD, Braak) using Pearson correlation (<xref rid="R95" ref-type="bibr">Pearson, 1931</xref>). We used the same method for clinical scores and neuropathological scores in UPenn and Emory datasets. For UPenn and Emory, we determined if the module eigenprotein was significantly different from disease diagnosis and control using linear regression.</p></sec><sec id="S24"><title>Western blot validation</title><p id="P45">Brain homogenates (frontal cortex) in urea (50 &#x003bc;g) were mixed with Laemmli sample buffer and resolved by SDS-PAGE before an overnight wet transfer to nitrocellulose membranes (BioRad) as previously reported (<xref rid="R108" ref-type="bibr">Seyfried et al., 2017</xref>). Membranes were blocked with casein blocking buffer (Sigma B6429) and probed with primary polyclonal antibodies for Anti-PLCD1 antibody (Abcam #ab134936), anti-HEPACAM (Abcam #ab130769), anti-PADI2 antibody (Abcam #ab16478), anti-GAPDH antibody (Abcam #ab8245), and anti-Connexin-43 (Sigma #C6219) overnight at 4&#x000b0;C. Membranes were incubated with secondary antibodies conjugated to Alexa Fluor 680 (Invitrogen) or IRDye800 (Rockland) fluorophores for one hour at room temperature. Images were captured using an Odyssey Infrared Imaging System (Li-Cor Biosciences). Protein densitometry for relative quantification was performed using ImageJ open source software. For GJA1, the higher molecular weight band reflective of ubiquitination (<xref rid="R1" ref-type="bibr">Abreha et al., 2018</xref>) was analyzed separately from the lower molecular weight band. Densitometry was compared between AD and control using the Student&#x02019;s t test (<xref rid="R113" ref-type="bibr">Student, 1908</xref>).</p></sec><sec id="S25"><title>Differential expression analysis in PSP compared to AD</title><p id="P46">We used the set of differentially expressed genes in PSP compared to AD (FDR &#x0003c; 0.1) at the RNA and protein level. We correlated the fold-change in RNA level to the fold-change in protein level with linear regression and the Wald test to determine significance.</p></sec><sec id="S26"><title>Comparison of the AD proteome in prefrontal and temporal cortex</title><p id="P47">We created a prefrontal consensus proteomic network with the four prefrontal cortex cohorts (BLSA, MSBB, Banner, ACT) using the same methodology and parameters when creating the consensus proteomic network with all five proteomic cohorts (BLSA, MSBB, Banner, ACT, Mayo) as described above. For each prefrontal cohort, we calculated prefrontal consensus module preservation using the <italic>Z<sub>summary</sub></italic> in the Mayo proteomic temporal cortex cohort (<xref rid="R71" ref-type="bibr">Langfelder et al., 2011</xref>). <italic>Z<sub>summary</sub></italic> greater than 2 indicates module preservation and <italic>Z<sub>summary</sub></italic> greater than 10 indicated strong module preservation.</p></sec><sec id="S27"><title>Comparison of the AD proteome and transcriptome</title><p id="P48">We performed weighted co-expression network analysis (WGCNA) (<xref rid="R70" ref-type="bibr">Langfelder and Horvath, 2008</xref>) for only the Mayo proteomic and transcriptomic data resulting in a Mayo only proteomic network and transcriptomic network. Biweighted mid-correlations were calculated for all pairs of genes, and then a signed similarity matrix was created. The signed similarity matrix was then raised to power &#x003b2; to emphasize strong correlations and reduce the emphasis of weak correlations on an exponential scale. The resulting adjacency matrix was then transformed into a topological overlap matrix (TOM). Using 1 &#x02013; TOM as the distance measure, genes were hierarchically clustered (<xref rid="R93" ref-type="bibr">Parikshak et al., 2016</xref>).</p><p id="P49">We identified consensus proteomic modules overlapping with Mayo proteomic modules, and Mayo proteomic modules overlapping with Mayo transcriptomic modules using the Fisher&#x02019;s exact test (<xref rid="R32" ref-type="bibr">Fisher, 1922</xref>).</p></sec><sec id="S28"><title>Module Connectivity in Proteomic versus Transcriptomic Modules</title><p id="P50">Hub genes had high eigengene-based connectivity (kME) (<xref rid="R69" ref-type="bibr">Langfelder and Horvath, 2007</xref>; <xref rid="R126" ref-type="bibr">Zhang and Horvath, 2005</xref>).</p><p id="P51">We compared intersecting genes from Mayo proteomic modules that had significant hypergeometric overlap with Mayo transcriptomic modules. To calculate the shortest path between all pairs of genes in a module, we first removed all edges with correlations from the adjacency matrix lower than the 75<sup>th</sup> percentile. The shortest path was calculated with the igraph package in R (<xref rid="R18" ref-type="bibr">Csardi and Nepusz, 2006</xref>). For pairs of genes that were connected, we determined if the mean shortest path in the Mayo proteomic module was significantly different than the mean shortest path in the Mayo transcriptomic modules using Student&#x02019;s t test (<xref rid="R113" ref-type="bibr">Student, 1908</xref>). We calculated the clustering coefficient, which measures the connectivity among a gene&#x02019;s neighbors, using the WGCNA R package (<xref rid="R70" ref-type="bibr">Langfelder and Horvath, 2008</xref>) and determined if it was significantly different in Mayo proteomic modules versus transcriptomic modules using Student&#x02019;s t test (<xref rid="R113" ref-type="bibr">Student, 1908</xref>).</p></sec><sec id="S29"><title>Genetic Risk GWAS Enrichment</title><p id="P52">We considered a module to be correlated with APOE &#x003b5;4 allele if the correlation was significant in at least one of the three cohorts with APOE genotypes (Mayo, BLSA, Banner)</p><p id="P53">GWAS summary data were obtained from the International Genomics of Alzheimer&#x02019;s Project (IGAP) for AD (<xref rid="R67" ref-type="bibr">Lambert et al., 2013</xref>) and for PSP(<xref rid="R51" ref-type="bibr">H&#x000f6;glinger et al., 2011</xref>). We used the MAGMA approach (<xref rid="R23" ref-type="bibr">de Leeuw et al., 2015</xref>) to assign each gene a score based on the best p value of a SNP in a given GWAS study within 20kB of the gene, and then set a p value cut-off at 0.05 to define the gene as included in the common variant set related to that study. We performed enrichment analysis with logistic regression controlling for gene length and other biases (<xref rid="R93" ref-type="bibr">Parikshak et al., 2016</xref>).</p></sec></sec></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Table S1</label><media xlink:href="NIHMS1710525-supplement-Table_S1.xlsx" orientation="portrait" id="d40e1464" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Table S2</label><media xlink:href="NIHMS1710525-supplement-Table_S2.xlsx" orientation="portrait" id="d40e1468" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>Table S4</label><media xlink:href="NIHMS1710525-supplement-Table_S4.xlsx" orientation="portrait" id="d40e1472" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><label>Supplement</label><media xlink:href="NIHMS1710525-supplement-Supplement.pdf" orientation="portrait" id="d40e1476" position="anchor"/></supplementary-material></sec></body><back><ack id="S30"><title>ACKNOWLEDGMENTS</title><p id="P54">Support for this research was provided by funding from the National Institute of Neurological Disorders and Stroke (NINDS), United States (R25NS065723 Translational Neuroscience Training Grant, P30NS055077 NINDS Emory Neuroscience Core) and National Institute on Aging (NIA), United States (R01AG053960, R01AG057911, R01AG061800, RF1AG057470, RF1AG05747101, U01AG046161 Accelerating Medicine Partnership for Alzheimer&#x02019;s disease, P50AG025688 Emory Alzheimer&#x02019;s Disease Research Center).</p><p id="P55">The results published here are in whole or in part based on data obtained from the AMP-AD Knowledge Portal (<ext-link ext-link-type="uri" xlink:href="https://adknowledgeportal.synapse.org/">https://adknowledgeportal.synapse.org/</ext-link>). BLSA data were generated from postmortem brain tissue collected through the National Institute on Aging&#x02019;s Baltimore Longitudinal Study of Aging and provided by Dr. Levey from Emory University.</p><p id="P56">ACT data were generated from postmortem brain tissue collected through the Adult Changes in Thought study (E. Larsen), and The University of Washington ADRC (T. Montine), with the proteomics provided by Drs. Seyfried, Lah, and Levey from Emory University (NIA U01 AG046161; NIA P50 AG025688; NIA P30 NS055077).</p><p id="P57">MSBB data were provided by Dr. Levey from Emory University based on postmortem brain tissue collected through the Mount Sinai VA Medical Center Brain Bank provided by Dr. Eric Schadt from Mount Sinai School of Medicine.</p><p id="P58">Banner data were provided by Dr. Levey from Emory University. A portion of these data were generated from samples collected through the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona. The Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson&#x02019;s Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer&#x02019;s Disease Core Center), the Arizona Department of Health Services, United States (contract 211002, Arizona Alzheimer&#x02019;s Research Center), the Arizona Biomedical Research Commission, United States (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson&#x02019;s Disease Consortium) and the Michael J. Fox Foundation for Parkinson&#x02019;s Research, United States.</p><p id="P59">Mayo data were provided by Dr. Levey from Emory University based on postmortem brain tissue provided by the following sources: The Mayo Clinic Alzheimers Disease Genetic Studies, led by Dr. Nilufer Taner and Dr. Steven G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimers Disease Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, NINDS grant R01 NS080820, CurePSP Foundation, United States, and support from Mayo Foundation, United States. Study data includes samples collected through the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona. The Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinsons Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimers Disease Core Center), the Arizona Department of Health Services, United States (contract 211002, Arizona Alzheimers Research Center), the Arizona Biomedical Research Commission, United States (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson&#x02019;s Disease Consortium) and the Michael J. Fox Foundation for Parkinsons Research, United States.</p><p id="P60">UPenn data were generated from postmortem brain tissue collected through the University of Pennsylvania and provided by Dr. Levey from Emory University. Emory data were generated from postmortem brain tissue collected through the Emory Alzheimers Disease Research Center Brain Bank and provided by Dr. Levey from Emory University.</p></ack><fn-group><fn id="FN2"><p id="P61">SUPPLEMENTAL INFORMATION</p><p id="P62"><xref rid="SD4" ref-type="supplementary-material">Supplemental Information</xref> can be found online at <ext-link ext-link-type="doi" xlink:href="10.1016/j.celrep.2020.107807">https://doi.org/10.1016/j.celrep.2020.107807</ext-link>.</p></fn><fn fn-type="COI-statement" id="FN3"><p id="P63">DECLARATION OF INTERESTS</p><p id="P64">The authors declare no competing interests.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><mixed-citation publication-type="journal"><name><surname>Abreha</surname><given-names>MH</given-names></name>, <name><surname>Dammer</surname><given-names>EB</given-names></name>, <name><surname>Ping</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>T</given-names></name>, <name><surname>Duong</surname><given-names>DM</given-names></name>, <name><surname>Gearing</surname><given-names>M</given-names></name>, <name><surname>Lah</surname><given-names>JJ</given-names></name>, <name><surname>Levey</surname><given-names>AI</given-names></name>, and <name><surname>Seyfried</surname><given-names>NT</given-names></name> (<year>2018</year>). <article-title>Quantitative Analysis of the Brain Ubiquitylome in Alzheimer&#x02019;s Disease</article-title>. <source>Proteomics</source>
<volume>18</volume>, <fpage>e1800108</fpage>.<pub-id pub-id-type="pmid">30230243</pub-id></mixed-citation></ref><ref id="R2"><mixed-citation publication-type="journal"><name><surname>Allen</surname><given-names>M</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Burgess</surname><given-names>JD</given-names></name>, <name><surname>Watzlawik</surname><given-names>J</given-names></name>, <name><surname>Serie</surname><given-names>DJ</given-names></name>, <name><surname>Younkin</surname><given-names>CS</given-names></name>, <name><surname>Nguyen</surname><given-names>T</given-names></name>, <name><surname>Malphrus</surname><given-names>KG</given-names></name>, <name><surname>Lincoln</surname><given-names>S</given-names></name>, <name><surname>Carrasquillo</surname><given-names>MM</given-names></name>, <etal/> (<year>2018</year>). <article-title>Conserved brain myelination networks are altered in Alzheimer&#x02019;s and other neurodegenerative diseases</article-title>. <source>Alzheimers Dement</source>. <volume>14</volume>, <fpage>352</fpage>&#x02013;<lpage>366</lpage>.<pub-id pub-id-type="pmid">29107053</pub-id></mixed-citation></ref><ref id="R3"><mixed-citation publication-type="journal"><collab>Alzheimer&#x02019;s Association</collab> (<year>2019</year>). <article-title>2019 Alzheimer&#x02019;s disease facts and figures</article-title>. <source>Alzheimers Dement</source>. <volume>15</volume>, <fpage>321</fpage>&#x02013;<lpage>387</lpage>.</mixed-citation></ref><ref id="R4"><mixed-citation publication-type="journal"><name><surname>Andreev</surname><given-names>VP</given-names></name>, <name><surname>Petyuk</surname><given-names>VA</given-names></name>, <name><surname>Brewer</surname><given-names>HM</given-names></name>, <name><surname>Karpievitch</surname><given-names>YV</given-names></name>, <name><surname>Xie</surname><given-names>F</given-names></name>, <name><surname>Clarke</surname><given-names>J</given-names></name>, <name><surname>Camp</surname><given-names>D</given-names></name>, <name><surname>Smith</surname><given-names>RD</given-names></name>, <name><surname>Lieberman</surname><given-names>AP</given-names></name>, <name><surname>Albin</surname><given-names>RL</given-names></name>, <etal/> (<year>2012</year>). <article-title>Label-free quantitative LC-MS proteomics of Alzheimer&#x02019;s disease and normally aged human brains</article-title>. <source>J. Proteome Res</source>
<volume>11</volume>, <fpage>3053</fpage>&#x02013;<lpage>3067</lpage>.<pub-id pub-id-type="pmid">22559202</pub-id></mixed-citation></ref><ref id="R5"><mixed-citation publication-type="journal"><name><surname>Arendt</surname><given-names>T</given-names></name>, <name><surname>Stieler</surname><given-names>JT</given-names></name>, and <name><surname>Holzer</surname><given-names>M</given-names></name> (<year>2016</year>). <article-title>Tau and tauopathies</article-title>. <source>Brain Res. Bull</source>
<volume>126</volume>, <fpage>238</fpage>&#x02013;<lpage>292</lpage>.<pub-id pub-id-type="pmid">27615390</pub-id></mixed-citation></ref><ref id="R6"><mixed-citation publication-type="journal"><name><surname>Arnold</surname><given-names>SE</given-names></name>, <name><surname>Toledo</surname><given-names>JB</given-names></name>, <name><surname>Appleby</surname><given-names>DH</given-names></name>, <name><surname>Xie</surname><given-names>SX</given-names></name>, <name><surname>Wang</surname><given-names>L-S</given-names></name>, <name><surname>Baek</surname><given-names>Y</given-names></name>, <name><surname>Wolk</surname><given-names>DA</given-names></name>, <name><surname>Lee</surname><given-names>EB</given-names></name>, <name><surname>Miller</surname><given-names>BL</given-names></name>, <name><surname>Lee</surname><given-names>VM-Y</given-names></name>, and <name><surname>Trojanowski</surname><given-names>JQ</given-names></name> (<year>2013</year>). <article-title>Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases</article-title>. <source>J. Comp. Neurol</source>
<volume>521</volume>, <fpage>4339</fpage>&#x02013;<lpage>4355</lpage>.<pub-id pub-id-type="pmid">23881776</pub-id></mixed-citation></ref><ref id="R7"><mixed-citation publication-type="journal"><name><surname>Ashburner</surname><given-names>M</given-names></name>, <name><surname>Ball</surname><given-names>CA</given-names></name>, <name><surname>Blake</surname><given-names>JA</given-names></name>, <name><surname>Botstein</surname><given-names>D</given-names></name>, <name><surname>Butler</surname><given-names>H</given-names></name>, <name><surname>Cherry</surname><given-names>JM</given-names></name>, <name><surname>Davis</surname><given-names>AP</given-names></name>, <name><surname>Dolinski</surname><given-names>K</given-names></name>, <name><surname>Dwight</surname><given-names>SS</given-names></name>, <name><surname>Eppig</surname><given-names>JT</given-names></name>, <etal/>; <collab>The Gene Ontology Consortium</collab> (<year>2000</year>). <article-title>Gene ontology: tool for the unification of biology</article-title>. <source>Nat. Genet</source>
<volume>25</volume>, <fpage>25</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">10802651</pub-id></mixed-citation></ref><ref id="R8"><mixed-citation publication-type="journal"><name><surname>Bachiller</surname><given-names>S</given-names></name>, <name><surname>Jim&#x000e9;nez-Ferrer</surname><given-names>I</given-names></name>, <name><surname>Paulus</surname><given-names>A</given-names></name>, <name><surname>Yang</surname><given-names>Y</given-names></name>, <name><surname>Swanberg</surname><given-names>M</given-names></name>, <name><surname>Deierborg</surname><given-names>T</given-names></name>, and <name><surname>Boza-Serrano</surname><given-names>A</given-names></name> (<year>2018</year>). <article-title>Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response</article-title>. <source>Front. Cell. Neurosci</source>
<volume>12</volume>, <fpage>488</fpage>.<pub-id pub-id-type="pmid">30618635</pub-id></mixed-citation></ref><ref id="R9"><mixed-citation publication-type="journal"><name><surname>Bonham</surname><given-names>LW</given-names></name>, <name><surname>Karch</surname><given-names>CM</given-names></name>, <name><surname>Fan</surname><given-names>CC</given-names></name>, <name><surname>Tan</surname><given-names>C</given-names></name>, <name><surname>Geier</surname><given-names>EG</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Wen</surname><given-names>N</given-names></name>, <name><surname>Broce</surname><given-names>IJ</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Barkovich</surname><given-names>MJ</given-names></name>, <etal/>
<article-title>International FTD-Genomics Consortium (IFGC); International Parkinson&#x02019;s Disease Genetics Consortium (IPDGC); International Genomics of Alzheimer&#x02019;s Project (IGAP) (2018). CXCR4 involvement in neurodegenerative diseases</article-title>. <source>Transl. Psychiatry</source>
<volume>8</volume>, <fpage>73</fpage>.<pub-id pub-id-type="pmid">29636460</pub-id></mixed-citation></ref><ref id="R10"><mixed-citation publication-type="journal"><name><surname>Braak</surname><given-names>H</given-names></name>, and <name><surname>Braak</surname><given-names>E</given-names></name> (<year>1991</year>). <article-title>Neuropathological stageing of Alzheimer-related changes</article-title>. <source>Acta Neuropathol</source>. <volume>82</volume>, <fpage>239</fpage>&#x02013;<lpage>259</lpage>.<pub-id pub-id-type="pmid">1759558</pub-id></mixed-citation></ref><ref id="R11"><mixed-citation publication-type="journal"><name><surname>Braak</surname><given-names>H</given-names></name>, <name><surname>Del Tredici</surname><given-names>K</given-names></name>, <name><surname>R&#x000fc;b</surname><given-names>U</given-names></name>, <name><surname>de Vos</surname><given-names>RAI</given-names></name>, <name><surname>Jansen Steur</surname><given-names>ENH</given-names></name>, and <name><surname>Braak</surname><given-names>E</given-names></name> (<year>2003</year>). <article-title>Staging of brain pathology related to sporadic Parkinson&#x02019;s disease</article-title>. <source>Neurobiol. Aging</source>
<volume>24</volume>, <fpage>197</fpage>&#x02013;<lpage>211</lpage>.<pub-id pub-id-type="pmid">12498954</pub-id></mixed-citation></ref><ref id="R12"><mixed-citation publication-type="journal"><name><surname>Briston</surname><given-names>T</given-names></name>, and <name><surname>Hicks</surname><given-names>AR</given-names></name> (<year>2018</year>). <article-title>Mitochondrial dysfunction and neurodegenerative proteinopathies: mechanisms and prospects for therapeutic intervention</article-title>. <source>Biochem. Soc. Trans</source>
<volume>46</volume>, <fpage>829</fpage>&#x02013;<lpage>842</lpage>.<pub-id pub-id-type="pmid">29986938</pub-id></mixed-citation></ref><ref id="R13"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>D</given-names></name>, <name><surname>Nalls</surname><given-names>MA</given-names></name>, <name><surname>Hallgr&#x000ed;msd&#x000f3;ttir</surname><given-names>IB</given-names></name>, <name><surname>Hunkapiller</surname><given-names>J</given-names></name>, <name><surname>van der Brug</surname><given-names>M</given-names></name>, <name><surname>Cai</surname><given-names>F</given-names></name>, <name><surname>Kerchner</surname><given-names>GA</given-names></name>, <name><surname>Ayalon</surname><given-names>G</given-names></name>, <name><surname>Bingol</surname><given-names>B</given-names></name>, <name><surname>Sheng</surname><given-names>M</given-names></name>, <etal/>; <collab>International Parkinson&#x02019;s Disease Genomics Consortium</collab>; <collab>23andMe Research Team</collab> (<year>2017</year>). <article-title>A meta-analysis of genome-wide association studies identifies 17 new Parkinson&#x02019;s disease risk loci</article-title>. <source>Nat. Genet</source>
<volume>49</volume>, <fpage>1511</fpage>&#x02013;<lpage>1516</lpage>.<pub-id pub-id-type="pmid">28892059</pub-id></mixed-citation></ref><ref id="R14"><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>JA</given-names></name>, <name><surname>Chen</surname><given-names>Z</given-names></name>, <name><surname>Won</surname><given-names>H</given-names></name>, <name><surname>Huang</surname><given-names>AY</given-names></name>, <name><surname>Lowe</surname><given-names>JK</given-names></name>, <name><surname>Wojta</surname><given-names>K</given-names></name>, <name><surname>Yokoyama</surname><given-names>JS</given-names></name>, <name><surname>Bensimon</surname><given-names>G</given-names></name>, <name><surname>Leigh</surname><given-names>PN</given-names></name>, <name><surname>Payan</surname><given-names>C</given-names></name>, <etal/> (<year>2018</year>). <article-title>Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases</article-title>. <source>Mol. Neurodegener</source>
<volume>13</volume>, <fpage>41</fpage>.<pub-id pub-id-type="pmid">30089514</pub-id></mixed-citation></ref><ref id="R15"><mixed-citation publication-type="journal"><name><surname>Colacurcio</surname><given-names>DJ</given-names></name>, and <name><surname>Nixon</surname><given-names>RA</given-names></name> (<year>2016</year>). <article-title>Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease</article-title>. <source>Ageing Res. Rev</source>
<volume>32</volume>, <fpage>75</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">27197071</pub-id></mixed-citation></ref><ref id="R16"><mixed-citation publication-type="journal"><name><surname>Coppola</surname><given-names>G</given-names></name>, <name><surname>Chinnathambi</surname><given-names>S</given-names></name>, <name><surname>Lee</surname><given-names>JJ</given-names></name>, <name><surname>Dombroski</surname><given-names>BA</given-names></name>, <name><surname>Baker</surname><given-names>MC</given-names></name>, <name><surname>Soto-Ortolaza</surname><given-names>AI</given-names></name>, <name><surname>Lee</surname><given-names>SE</given-names></name>, <name><surname>Klein</surname><given-names>E</given-names></name>, <name><surname>Huang</surname><given-names>AY</given-names></name>, <name><surname>Sears</surname><given-names>R</given-names></name>, <etal/>; <collab>Alzheimer&#x02019;s Disease Genetics Consortium</collab> (<year>2012</year>). <article-title>Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer&#x02019;s diseases</article-title>. <source>Hum. Mol. Genet</source>
<volume>21</volume>, <fpage>3500</fpage>&#x02013;<lpage>3512</lpage>.<pub-id pub-id-type="pmid">22556362</pub-id></mixed-citation></ref><ref id="R17"><mixed-citation publication-type="journal"><name><surname>Cox</surname><given-names>J</given-names></name>, and <name><surname>Mann</surname><given-names>M</given-names></name> (<year>2008</year>). <article-title>MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification</article-title>. <source>Nat. Biotechnol</source>
<volume>26</volume>, <fpage>1367</fpage>&#x02013;<lpage>1372</lpage>.<pub-id pub-id-type="pmid">19029910</pub-id></mixed-citation></ref><ref id="R18"><mixed-citation publication-type="journal"><name><surname>Csardi</surname><given-names>G</given-names></name>, and <name><surname>Nepusz</surname><given-names>T</given-names></name> (<year>2006</year>). <article-title>The igraph software package for complex network research</article-title>. <source>Int. J. Complex Syst</source>
<volume>1695</volume>, <fpage>1</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="R19"><mixed-citation publication-type="journal"><name><surname>Cummings</surname><given-names>JL</given-names></name> (<year>2003</year>). <article-title>Toward a molecular neuropsychiatry of neurodegenerative diseases</article-title>. <source>Ann. Neurol</source>
<volume>54</volume>, <fpage>147</fpage>&#x02013;<lpage>154</lpage>.<pub-id pub-id-type="pmid">12891666</pub-id></mixed-citation></ref><ref id="R20"><mixed-citation publication-type="journal"><name><surname>Darmellah</surname><given-names>A</given-names></name>, <name><surname>Rayah</surname><given-names>A</given-names></name>, <name><surname>Auger</surname><given-names>R</given-names></name>, <name><surname>Cuif</surname><given-names>M-H</given-names></name>, <name><surname>Prigent</surname><given-names>M</given-names></name>,<name><surname>Arpin</surname><given-names>M</given-names></name>, <name><surname>Alcover</surname><given-names>A</given-names></name>, <name><surname>Delarasse</surname><given-names>C</given-names></name>, and <name><surname>Kanellopoulos</surname><given-names>JM</given-names></name> (<year>2012</year>). <article-title>Ezrin/radixin/moesin are required for the purinergic P2X7 receptor (P2X7R)-dependent processing of the amyloid precursor protein</article-title>. <source>J. Biol. Chem</source>
<volume>287</volume>, <fpage>34583</fpage>&#x02013;<lpage>34595</lpage>.<pub-id pub-id-type="pmid">22891241</pub-id></mixed-citation></ref><ref id="R21"><mixed-citation publication-type="journal"><name><surname>Davidson</surname><given-names>Y</given-names></name>, <name><surname>Kelley</surname><given-names>T</given-names></name>, <name><surname>Mackenzie</surname><given-names>IRA</given-names></name>, <name><surname>Pickering-Brown</surname><given-names>S</given-names></name>, <name><surname>Du Plessis</surname><given-names>D</given-names></name>, <name><surname>Neary</surname><given-names>D</given-names></name>, <name><surname>Snowden</surname><given-names>JS</given-names></name>, and <name><surname>Mann</surname><given-names>DMA</given-names></name> (<year>2007</year>). <article-title>Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43</article-title>. <source>Acta Neuropathol</source>. <volume>113</volume>, <fpage>521</fpage>&#x02013;<lpage>533</lpage>.<pub-id pub-id-type="pmid">17219193</pub-id></mixed-citation></ref><ref id="R22"><mixed-citation publication-type="journal"><name><surname>De Jager</surname><given-names>PL</given-names></name>, <name><surname>Yang</surname><given-names>H-S</given-names></name>, and <name><surname>Bennett</surname><given-names>DA</given-names></name> (<year>2018</year>). <article-title>Deconstructing and targeting the genomic architecture of human neurodegeneration</article-title>. <source>Nat. Neurosci</source>
<volume>21</volume>, <fpage>1310</fpage>&#x02013;<lpage>1317</lpage>.<pub-id pub-id-type="pmid">30258235</pub-id></mixed-citation></ref><ref id="R23"><mixed-citation publication-type="journal"><name><surname>de Leeuw</surname><given-names>CA</given-names></name>, <name><surname>Mooij</surname><given-names>JM</given-names></name>, <name><surname>Heskes</surname><given-names>T</given-names></name>, and <name><surname>Posthuma</surname><given-names>D</given-names></name> (<year>2015</year>). <article-title>MAGMA: generalized gene-set analysis of GWAS data</article-title>. <source>PLoS Comput. Biol</source>
<volume>11</volume>, <fpage>e1004219</fpage>.<pub-id pub-id-type="pmid">25885710</pub-id></mixed-citation></ref><ref id="R24"><mixed-citation publication-type="journal"><name><surname>De Strooper</surname><given-names>B</given-names></name>, and <name><surname>Karran</surname><given-names>E</given-names></name> (<year>2016</year>). <article-title>The Cellular Phase of Alzheimer&#x02019;s Disease</article-title>. <source>Cell</source>
<volume>164</volume>, <fpage>603</fpage>&#x02013;<lpage>615</lpage>.<pub-id pub-id-type="pmid">26871627</pub-id></mixed-citation></ref><ref id="R25"><mixed-citation publication-type="journal"><name><surname>Desikan</surname><given-names>RS</given-names></name>, <name><surname>Schork</surname><given-names>AJ</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Witoelar</surname><given-names>A</given-names></name>, <name><surname>Sharma</surname><given-names>M</given-names></name>, <name><surname>McEvoy</surname><given-names>LK</given-names></name>, <name><surname>Holland</surname><given-names>D</given-names></name>, <name><surname>Brewer</surname><given-names>JB</given-names></name>, <name><surname>Chen</surname><given-names>C-H</given-names></name>, <name><surname>Thompson</surname><given-names>WK</given-names></name>, <etal/>; <collab>ADNI, ADGC, GERAD, CHARGE and IPDGC Investigators</collab> (<year>2015</year>). <article-title>Genetic overlap between Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease at the MAPT locus</article-title>. <source>Mol. Psychiatry</source>
<volume>20</volume>, <fpage>1588</fpage>&#x02013;<lpage>1595</lpage>.<pub-id pub-id-type="pmid">25687773</pub-id></mixed-citation></ref><ref id="R26"><mixed-citation publication-type="journal"><name><surname>Dickson</surname><given-names>DW</given-names></name>, <name><surname>Ahmed</surname><given-names>Z</given-names></name>, <name><surname>Algom</surname><given-names>AA</given-names></name>, <name><surname>Tsuboi</surname><given-names>Y</given-names></name>, and <name><surname>Josephs</surname><given-names>KA</given-names></name> (<year>2010</year>). <article-title>Neuropathology of variants of progressive supranuclear palsy</article-title>. <source>Curr. Opin. Neurol</source>
<volume>23</volume>, <fpage>394</fpage>&#x02013;<lpage>400</lpage>.<pub-id pub-id-type="pmid">20610990</pub-id></mixed-citation></ref><ref id="R27"><mixed-citation publication-type="journal"><name><surname>Dzamba</surname><given-names>D</given-names></name>, <name><surname>Harantova</surname><given-names>L</given-names></name>, <name><surname>Butenko</surname><given-names>O</given-names></name>, and <name><surname>Anderova</surname><given-names>M</given-names></name> (<year>2016</year>). <article-title>Glial Cells - The Key Elements of Alzheimer&#x02019;s Disease</article-title>. <source>Curr. Alzheimer Res</source>
<volume>13</volume>, <fpage>894</fpage>&#x02013;<lpage>911</lpage>.<pub-id pub-id-type="pmid">26825092</pub-id></mixed-citation></ref><ref id="R28"><mixed-citation publication-type="journal"><name><surname>Efthymiou</surname><given-names>AG</given-names></name>, and <name><surname>Goate</surname><given-names>AM</given-names></name> (<year>2017</year>). <article-title>Late onset Alzheimer&#x02019;s disease genetics implicates microglial pathways in disease risk</article-title>. <source>Mol. Neurodegener</source>
<volume>12</volume>, <fpage>43</fpage>.<pub-id pub-id-type="pmid">28549481</pub-id></mixed-citation></ref><ref id="R29"><mixed-citation publication-type="journal"><name><surname>Erkkinen</surname><given-names>MG</given-names></name>, <name><surname>Kim</surname><given-names>M-O</given-names></name>, and <name><surname>Geschwind</surname><given-names>MD</given-names></name> (<year>2018</year>). <article-title>Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases</article-title>. <source>Cold Spring Harb. Perspect. Biol</source>
<volume>10</volume>, <fpage>a033118</fpage>.<pub-id pub-id-type="pmid">28716886</pub-id></mixed-citation></ref><ref id="R30"><mixed-citation publication-type="journal"><name><surname>Fern&#x000e1;ndez-Botr&#x000e1;n</surname><given-names>R</given-names></name>, <name><surname>Ahmed</surname><given-names>Z</given-names></name>, <name><surname>Crespo</surname><given-names>FA</given-names></name>, <name><surname>Gatenbee</surname><given-names>C</given-names></name>, <name><surname>Gonzalez</surname><given-names>J</given-names></name>, <name><surname>Dickson</surname><given-names>DW</given-names></name>, and <name><surname>Litvan</surname><given-names>I</given-names></name> (<year>2011</year>). <article-title>Cytokine expression and microglial activation in progressive supranuclear palsy</article-title>. <source>Parkinsonism Relat. Disord</source>
<volume>17</volume>, <fpage>683</fpage>&#x02013;<lpage>688</lpage>.<pub-id pub-id-type="pmid">21741294</pub-id></mixed-citation></ref><ref id="R31"><mixed-citation publication-type="journal"><name><surname>Ferrari</surname><given-names>R</given-names></name>, <name><surname>Hernandez</surname><given-names>DG</given-names></name>, <name><surname>Nalls</surname><given-names>MA</given-names></name>, <name><surname>Rohrer</surname><given-names>JD</given-names></name>, <name><surname>Ramasamy</surname><given-names>A</given-names></name>, <name><surname>Kwok</surname><given-names>JBJ</given-names></name>, <name><surname>Dobson-Stone</surname><given-names>C</given-names></name>, <name><surname>Brooks</surname><given-names>WS</given-names></name>, <name><surname>Schofield</surname><given-names>PR</given-names></name>, <name><surname>Halliday</surname><given-names>GM</given-names></name>, <etal/> (<year>2014</year>). <article-title>Frontotemporal dementia and its subtypes: a genome-wide association study</article-title>. <source>Lancet Neurol</source>. <volume>13</volume>, <fpage>686</fpage>&#x02013;<lpage>699</lpage>.<pub-id pub-id-type="pmid">24943344</pub-id></mixed-citation></ref><ref id="R32"><mixed-citation publication-type="journal"><name><surname>Fisher</surname><given-names>RA</given-names></name> (<year>1922</year>). <article-title>On the interpretation of &#x003c7; 2 from contingency tables, and the calculation of P</article-title>. <source>J. R. Stat. Soc</source>
<volume>85</volume>, <fpage>87</fpage>&#x02013;<lpage>94</lpage>.</mixed-citation></ref><ref id="R33"><mixed-citation publication-type="journal"><name><surname>Forman</surname><given-names>MS</given-names></name>, <name><surname>Trojanowski</surname><given-names>JQ</given-names></name>, and <name><surname>Lee</surname><given-names>VM-Y</given-names></name> (<year>2004</year>). <article-title>Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic break-throughs</article-title>. <source>Nat. Med</source>
<volume>10</volume>, <fpage>1055</fpage>&#x02013;<lpage>1063</lpage>.<pub-id pub-id-type="pmid">15459709</pub-id></mixed-citation></ref><ref id="R34"><mixed-citation publication-type="journal"><name><surname>Gaiteri</surname><given-names>C</given-names></name>, <name><surname>Mostafavi</surname><given-names>S</given-names></name>, <name><surname>Honey</surname><given-names>CJ</given-names></name>, <name><surname>De Jager</surname><given-names>PL</given-names></name>, and <name><surname>Bennett</surname><given-names>DA</given-names></name> (<year>2016</year>). <article-title>Genetic variants in Alzheimer disease - molecular and brain network approaches</article-title>. <source>Nat. Rev. Neurol</source>
<volume>12</volume>, <fpage>413</fpage>&#x02013;<lpage>427</lpage>.<pub-id pub-id-type="pmid">27282653</pub-id></mixed-citation></ref><ref id="R35"><mixed-citation publication-type="journal"><name><surname>Gandal</surname><given-names>MJ</given-names></name>, <name><surname>Zhang</surname><given-names>P</given-names></name>, <name><surname>Hadjimichael</surname><given-names>E</given-names></name>, <name><surname>Walker</surname><given-names>RL</given-names></name>, <name><surname>Chen</surname><given-names>C</given-names></name>, <name><surname>Liu</surname><given-names>S</given-names></name>, <name><surname>Won</surname><given-names>H</given-names></name>, <name><surname>van Bakel</surname><given-names>H</given-names></name>, <name><surname>Varghese</surname><given-names>M</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <etal/> (<year>2018a</year>). <article-title>Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder</article-title>. <source>Science</source>
<volume>362</volume>, <fpage>eaat8127</fpage>.<pub-id pub-id-type="pmid">30545856</pub-id></mixed-citation></ref><ref id="R36"><mixed-citation publication-type="journal"><name><surname>Gandal</surname><given-names>MJ</given-names></name>, <name><surname>Haney</surname><given-names>JR</given-names></name>, <name><surname>Parikshak</surname><given-names>NN</given-names></name>, <name><surname>Leppa</surname><given-names>V</given-names></name>, <name><surname>Ramaswami</surname><given-names>G</given-names></name>, <name><surname>Hartl</surname><given-names>C</given-names></name>, <name><surname>Schork</surname><given-names>AJ</given-names></name>, <name><surname>Appadurai</surname><given-names>V</given-names></name>, <name><surname>Buil</surname><given-names>A</given-names></name>, <name><surname>Werge</surname><given-names>TM</given-names></name>, <etal/>; <collab>CommonMind Consortium; PsychENCODE Consortium; iPSYCH-BROAD Working Group</collab> (<year>2018b</year>). <article-title>Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap</article-title>. <source>Science</source>
<volume>359</volume>, <fpage>693</fpage>&#x02013;<lpage>697</lpage>.<pub-id pub-id-type="pmid">29439242</pub-id></mixed-citation></ref><ref id="R37"><mixed-citation publication-type="journal"><name><surname>Gautam</surname><given-names>V</given-names></name>, <name><surname>D&#x02019;Avanzo</surname><given-names>C</given-names></name>, <name><surname>Berezovska</surname><given-names>O</given-names></name>, <name><surname>Tanzi</surname><given-names>RE</given-names></name>, and <name><surname>Kovacs</surname><given-names>DM</given-names></name> (<year>2015</year>). <article-title>Synaptotagmins interact with APP and promote A&#x003b2; generation</article-title>. <source>Mol. Neurodegener</source>
<volume>10</volume>, <fpage>31</fpage>.<pub-id pub-id-type="pmid">26202512</pub-id></mixed-citation></ref><ref id="R38"><mixed-citation publication-type="journal"><collab>Gene Ontology Consortium</collab> (<year>2019</year>). <article-title>The Gene Ontology Resource: 20 years and still GOing strong</article-title>. <source>Nucleic Acids Res</source>. <volume>47</volume>, <fpage>D330</fpage>&#x02013;<lpage>D338</lpage>.<pub-id pub-id-type="pmid">30395331</pub-id></mixed-citation></ref><ref id="R39"><mixed-citation publication-type="journal"><name><surname>Geuens</surname><given-names>T</given-names></name>, <name><surname>Bouhy</surname><given-names>D</given-names></name>, and <name><surname>Timmerman</surname><given-names>V</given-names></name> (<year>2016</year>). <article-title>The hnRNP family: insights into their role in health and disease</article-title>. <source>Hum. Genet</source>
<volume>135</volume>, <fpage>851</fpage>&#x02013;<lpage>867</lpage>.<pub-id pub-id-type="pmid">27215579</pub-id></mixed-citation></ref><ref id="R40"><mixed-citation publication-type="journal"><name><surname>Goate</surname><given-names>A</given-names></name>, <name><surname>Chartier-Harlin</surname><given-names>MC</given-names></name>, <name><surname>Mullan</surname><given-names>M</given-names></name>, <name><surname>Brown</surname><given-names>J</given-names></name>, <name><surname>Crawford</surname><given-names>F</given-names></name>, <name><surname>Fidani</surname><given-names>L</given-names></name>, <name><surname>Giuffra</surname><given-names>L</given-names></name>, <name><surname>Haynes</surname><given-names>A</given-names></name>, <name><surname>Irving</surname><given-names>N</given-names></name>, <name><surname>James</surname><given-names>L</given-names></name>, <etal/> (<year>1991</year>). <article-title>Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer&#x02019;s disease</article-title>. <source>Nature</source>
<volume>349</volume>, <fpage>704</fpage>&#x02013;<lpage>706</lpage>.<pub-id pub-id-type="pmid">1671712</pub-id></mixed-citation></ref><ref id="R41"><mixed-citation publication-type="journal"><name><surname>Golde</surname><given-names>TE</given-names></name>, <name><surname>Estus</surname><given-names>S</given-names></name>, <name><surname>Usiak</surname><given-names>M</given-names></name>, <name><surname>Younkin</surname><given-names>LH</given-names></name>, and <name><surname>Younkin</surname><given-names>SG</given-names></name> (<year>1990</year>). <article-title>Expression of beta amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in Alzheimer&#x02019;s disease using PCR</article-title>. <source>Neuron</source>
<volume>4</volume>, <fpage>253</fpage>&#x02013;<lpage>267</lpage>.<pub-id pub-id-type="pmid">2106330</pub-id></mixed-citation></ref><ref id="R42"><mixed-citation publication-type="journal"><name><surname>Gonz&#x000e1;lez-Reyes</surname><given-names>RE</given-names></name>, <name><surname>Nava-Mesa</surname><given-names>MO</given-names></name>, <name><surname>Vargas-S&#x000e1;nchez</surname><given-names>K</given-names></name>, <name><surname>Ariza-Salamanca</surname><given-names>D</given-names></name>, and <name><surname>Mora-Mu&#x000f1;oz</surname><given-names>L</given-names></name> (<year>2017</year>). <article-title>Involvement of Astrocytes in Alzheimer&#x02019;s Disease from a Neuroinflammatory and Oxidative Stress Perspective</article-title>. <source>Front. Mol. Neurosci</source>
<volume>10</volume>, <fpage>427</fpage>.<pub-id pub-id-type="pmid">29311817</pub-id></mixed-citation></ref><ref id="R43"><mixed-citation publication-type="journal"><name><surname>Griffith</surname><given-names>M</given-names></name>, <name><surname>Griffith</surname><given-names>OL</given-names></name>, <name><surname>Coffman</surname><given-names>AC</given-names></name>, <name><surname>Weible</surname><given-names>JV</given-names></name>, <name><surname>McMichael</surname><given-names>JF</given-names></name>, <name><surname>Spies</surname><given-names>NC</given-names></name>, <name><surname>Koval</surname><given-names>J</given-names></name>, <name><surname>Das</surname><given-names>I</given-names></name>, <name><surname>Callaway</surname><given-names>MB</given-names></name>, <name><surname>Eldred</surname><given-names>JM</given-names></name>, <etal/> (<year>2013</year>). <article-title>DGIdb: mining the druggable genome</article-title>. <source>Nat. Methods</source>
<volume>10</volume>, <fpage>1209</fpage>&#x02013;<lpage>1210</lpage>.<pub-id pub-id-type="pmid">24122041</pub-id></mixed-citation></ref><ref id="R44"><mixed-citation publication-type="journal"><name><surname>Guise</surname><given-names>S</given-names></name>, <name><surname>Braguer</surname><given-names>D</given-names></name>, <name><surname>Carles</surname><given-names>G</given-names></name>, <name><surname>Delacourte</surname><given-names>A</given-names></name>, and <name><surname>Briand</surname><given-names>C</given-names></name> (<year>2001</year>). <article-title>Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells</article-title>. <source>J. Neurosci. Res</source>
<volume>63</volume>, <fpage>257</fpage>&#x02013;<lpage>267</lpage>.<pub-id pub-id-type="pmid">11170175</pub-id></mixed-citation></ref><ref id="R45"><mixed-citation publication-type="journal"><name><surname>Hansen</surname><given-names>DV</given-names></name>, <name><surname>Hanson</surname><given-names>JE</given-names></name>, and <name><surname>Sheng</surname><given-names>M</given-names></name> (<year>2018</year>). <article-title>Microglia in Alzheimer&#x02019;s disease</article-title>. <source>J. Cell Biol</source>
<volume>217</volume>, <fpage>459</fpage>&#x02013;<lpage>472</lpage>.<pub-id pub-id-type="pmid">29196460</pub-id></mixed-citation></ref><ref id="R46"><mixed-citation publication-type="journal"><name><surname>Hauw</surname><given-names>JJ</given-names></name>, <name><surname>Daniel</surname><given-names>SE</given-names></name>, <name><surname>Dickson</surname><given-names>D</given-names></name>, <name><surname>Horoupian</surname><given-names>DS</given-names></name>, <name><surname>Jellinger</surname><given-names>K</given-names></name>, <name><surname>Lantos</surname><given-names>PL</given-names></name>, <name><surname>McKee</surname><given-names>A</given-names></name>, <name><surname>Tabaton</surname><given-names>M</given-names></name>, and <name><surname>Litvan</surname><given-names>I</given-names></name> (<year>1994</year>). <article-title>Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)</article-title>. <source>Neurology</source>
<volume>44</volume>, <fpage>2015</fpage>&#x02013;<lpage>2019</lpage>.<pub-id pub-id-type="pmid">7969952</pub-id></mixed-citation></ref><ref id="R47"><mixed-citation publication-type="journal"><name><surname>Heckmann</surname><given-names>BL</given-names></name>, <name><surname>Teubner</surname><given-names>BJW</given-names></name>, <name><surname>Tummers</surname><given-names>B</given-names></name>, <name><surname>Boada-Romero</surname><given-names>E</given-names></name>, <name><surname>Harris</surname><given-names>L</given-names></name>, <name><surname>Yang</surname><given-names>M</given-names></name>, <name><surname>Guy</surname><given-names>CS</given-names></name>, <name><surname>Zakharenko</surname><given-names>SS</given-names></name>, and <name><surname>Green</surname><given-names>DR</given-names></name> (<year>2019</year>). <article-title>LC3-Associated Endocytosis Facilitates &#x003b2;-Amyloid Clearance and Mitigates Neurodegeneration in Murine Alzheimer&#x02019;s Disease</article-title>. <source>Cell</source>
<volume>178</volume>, <fpage>536</fpage>&#x02013;<lpage>551.e14</lpage>.<pub-id pub-id-type="pmid">31257024</pub-id></mixed-citation></ref><ref id="R48"><mixed-citation publication-type="journal"><name><surname>Heneka</surname><given-names>MT</given-names></name>, <name><surname>Carson</surname><given-names>MJ</given-names></name>, <name><surname>El Khoury</surname><given-names>J</given-names></name>, <name><surname>Landreth</surname><given-names>GE</given-names></name>, <name><surname>Brosseron</surname><given-names>F</given-names></name>, <name><surname>Feinstein</surname><given-names>DL</given-names></name>, <name><surname>Jacobs</surname><given-names>AH</given-names></name>, <name><surname>Wyss-Coray</surname><given-names>T</given-names></name>, <name><surname>Vitorica</surname><given-names>J</given-names></name>, <name><surname>Ransohoff</surname><given-names>RM</given-names></name>, <etal/> (<year>2015</year>). <article-title>Neuroinflammation in Alzheimer&#x02019;s disease</article-title>. <source>Lancet Neurol</source>. <volume>14</volume>, <fpage>388</fpage>&#x02013;<lpage>405</lpage>.<pub-id pub-id-type="pmid">25792098</pub-id></mixed-citation></ref><ref id="R49"><mixed-citation publication-type="journal"><name><surname>Hicke</surname><given-names>L</given-names></name> (<year>2001</year>). <article-title>Protein regulation by monoubiquitin</article-title>. <source>Nat. Rev. Mol. Cell Biol</source>
<volume>2</volume>, <fpage>195</fpage>&#x02013;<lpage>201</lpage>.<pub-id pub-id-type="pmid">11265249</pub-id></mixed-citation></ref><ref id="R50"><mixed-citation publication-type="journal"><name><surname>Hodes</surname><given-names>RJ</given-names></name>, and <name><surname>Buckholtz</surname><given-names>N</given-names></name> (<year>2016</year>). <article-title>Accelerating Medicines Partnership: Alzheimer&#x02019;s Disease (AMP-AD) Knowledge Portal Aids Alzheimer&#x02019;s Drug Discovery through Open Data Sharing</article-title>. <source>Expert Opin. Ther. Targets</source>
<volume>20</volume>, <fpage>389</fpage>&#x02013;<lpage>391</lpage>.<pub-id pub-id-type="pmid">26853544</pub-id></mixed-citation></ref><ref id="R51"><mixed-citation publication-type="journal"><name><surname>H&#x000f6;glinger</surname><given-names>GU</given-names></name>, <name><surname>Melhem</surname><given-names>NM</given-names></name>, <name><surname>Dickson</surname><given-names>DW</given-names></name>, <name><surname>Sleiman</surname><given-names>PMA</given-names></name>, <name><surname>Wang</surname><given-names>L-S</given-names></name>, <name><surname>Klei</surname><given-names>L</given-names></name>, <name><surname>Rademakers</surname><given-names>R</given-names></name>, <name><surname>de Silva</surname><given-names>R</given-names></name>, <name><surname>Litvan</surname><given-names>I</given-names></name>, <name><surname>Riley</surname><given-names>DE</given-names></name>, <etal/>; <collab>PSP Genetics Study Group</collab> (<year>2011</year>). <article-title>Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy</article-title>. <source>Nat. Genet</source>
<volume>43</volume>, <fpage>699</fpage>&#x02013;<lpage>705</lpage>.<pub-id pub-id-type="pmid">21685912</pub-id></mixed-citation></ref><ref id="R52"><mixed-citation publication-type="journal"><name><surname>Hong</surname><given-names>S</given-names></name>, <name><surname>Beja-Glasser</surname><given-names>VF</given-names></name>, <name><surname>Nfonoyim</surname><given-names>BM</given-names></name>, <name><surname>Frouin</surname><given-names>A</given-names></name>, <name><surname>Li</surname><given-names>S</given-names></name>, <name><surname>Ramakrishnan</surname><given-names>S</given-names></name>, <name><surname>Merry</surname><given-names>KM</given-names></name>, <name><surname>Shi</surname><given-names>Q</given-names></name>, <name><surname>Rosenthal</surname><given-names>A</given-names></name>, <name><surname>Barres</surname><given-names>BA</given-names></name>, <etal/> (<year>2016</year>). <article-title>Complement and microglia mediate early synapse loss in Alzheimer mouse models</article-title>. <source>Science</source>
<volume>352</volume>,<fpage>712</fpage>&#x02013;<lpage>716</lpage>.<pub-id pub-id-type="pmid">27033548</pub-id></mixed-citation></ref><ref id="R53"><mixed-citation publication-type="journal"><name><surname>Hopkins</surname><given-names>AL</given-names></name>, and <name><surname>Groom</surname><given-names>CR</given-names></name> (<year>2002</year>). <article-title>The druggable genome</article-title>. <source>Nat. Rev. Drug Discov</source>
<volume>1</volume>, <fpage>727</fpage>&#x02013;<lpage>730</lpage>.<pub-id pub-id-type="pmid">12209152</pub-id></mixed-citation></ref><ref id="R54"><mixed-citation publication-type="journal"><name><surname>Hyman</surname><given-names>BT</given-names></name>, <name><surname>Phelps</surname><given-names>CH</given-names></name>, <name><surname>Beach</surname><given-names>TG</given-names></name>, <name><surname>Bigio</surname><given-names>EH</given-names></name>, <name><surname>Cairns</surname><given-names>NJ</given-names></name>, <name><surname>Carrillo</surname><given-names>MC</given-names></name>, <name><surname>Dickson</surname><given-names>DW</given-names></name>, <name><surname>Duyckaerts</surname><given-names>C</given-names></name>, <name><surname>Frosch</surname><given-names>MP</given-names></name>, <name><surname>Masliah</surname><given-names>E</given-names></name>, <etal/> (<year>2012</year>). <article-title>National Institute on Aging-Alzheimer&#x02019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x02019;s disease</article-title>. <source>Alzheimers Dement</source>. <volume>8</volume>, <fpage>1</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">22265587</pub-id></mixed-citation></ref><ref id="R55"><mixed-citation publication-type="journal"><name><surname>Ishizawa</surname><given-names>K</given-names></name>, and <name><surname>Dickson</surname><given-names>DW</given-names></name> (<year>2001</year>). <article-title>Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration</article-title>. <source>J. Neuropathol. Exp. Neurol</source>
<volume>60</volume>, <fpage>647</fpage>&#x02013;<lpage>657</lpage>.<pub-id pub-id-type="pmid">11398841</pub-id></mixed-citation></ref><ref id="R56"><mixed-citation publication-type="journal"><name><surname>Ising</surname><given-names>C</given-names></name>, <name><surname>Venegas</surname><given-names>C</given-names></name>, <name><surname>Zhang</surname><given-names>S</given-names></name>, <name><surname>Scheiblich</surname><given-names>H</given-names></name>, <name><surname>Schmidt</surname><given-names>SV</given-names></name>, <name><surname>Vieira-Saecker</surname><given-names>A</given-names></name>, <name><surname>Schwartz</surname><given-names>S</given-names></name>, <name><surname>Albasset</surname><given-names>S</given-names></name>, <name><surname>McManus</surname><given-names>RM</given-names></name>, <name><surname>Tejera</surname><given-names>D</given-names></name>, <etal/> (<year>2019</year>). <article-title>NLRP3 inflammasome activation drives tau pathology</article-title>. <source>Nature</source>
<volume>575</volume>, <fpage>669</fpage>&#x02013;<lpage>673</lpage>.<pub-id pub-id-type="pmid">31748742</pub-id></mixed-citation></ref><ref id="R57"><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>ECB</given-names></name>, <name><surname>Dammer</surname><given-names>EB</given-names></name>, <name><surname>Duong</surname><given-names>DM</given-names></name>, <name><surname>Yin</surname><given-names>L</given-names></name>, <name><surname>Thambisetty</surname><given-names>M</given-names></name>, <name><surname>Troncoso</surname><given-names>JC</given-names></name>, <name><surname>Lah</surname><given-names>JJ</given-names></name>, <name><surname>Levey</surname><given-names>AI</given-names></name>, and <name><surname>Seyfried</surname><given-names>NT</given-names></name> (<year>2018</year>). <article-title>Deep proteomic network analysis of Alzheimer&#x02019;s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease</article-title>. <source>Mol. Neurodegener</source>
<volume>13</volume>, <fpage>52</fpage>.<pub-id pub-id-type="pmid">30286791</pub-id></mixed-citation></ref><ref id="R58"><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>ECB</given-names></name>, <name><surname>Dammer</surname><given-names>EB</given-names></name>, <name><surname>Duong</surname><given-names>DM</given-names></name>, <name><surname>Ping</surname><given-names>L</given-names></name>, <name><surname>Zhou</surname><given-names>M</given-names></name>, <name><surname>Yin</surname><given-names>L</given-names></name>, <name><surname>Higginbotham</surname><given-names>LA</given-names></name>, <name><surname>Guajardo</surname><given-names>A</given-names></name>, <name><surname>White</surname><given-names>B</given-names></name>, <name><surname>Troncoso</surname><given-names>JC</given-names></name>, <etal/> (<year>2020</year>). <article-title>Large-scale proteomic analysis of Alzheimer&#x02019;s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation</article-title>. <source>Nat. Med</source>
<volume>26</volume>, <fpage>769</fpage>&#x02013;<lpage>780</lpage>.<pub-id pub-id-type="pmid">32284590</pub-id></mixed-citation></ref><ref id="R59"><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>SV</given-names></name>, and <name><surname>Kounatidis</surname><given-names>I</given-names></name> (<year>2017</year>). <article-title>Nuclear Factor-Kappa B and Alzheimer Disease, Unifying Genetic and Environmental Risk Factors from Cell to Humans</article-title>. <source>Front. Immunol</source>
<volume>8</volume>.</mixed-citation></ref><ref id="R60"><mixed-citation publication-type="journal"><name><surname>Kajiwara</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>E</given-names></name>, <name><surname>Wang</surname><given-names>M</given-names></name>, <name><surname>Sin</surname><given-names>WC</given-names></name>, <name><surname>Brennand</surname><given-names>KJ</given-names></name>, <name><surname>Schadt</surname><given-names>E</given-names></name>, <name><surname>Naus</surname><given-names>CC</given-names></name>, <name><surname>Buxbaum</surname><given-names>J</given-names></name>, and <name><surname>Zhang</surname><given-names>B</given-names></name> (<year>2018</year>). <article-title>GJA1 (connexin43) is a key regulator of Alzheimer&#x02019;s disease pathogenesis</article-title>. <source>Acta Neuropathol. Commun</source>
<volume>6</volume>, <fpage>144</fpage>.<pub-id pub-id-type="pmid">30577786</pub-id></mixed-citation></ref><ref id="R61"><mixed-citation publication-type="journal"><name><surname>Karch</surname><given-names>CM</given-names></name>, and <name><surname>Goate</surname><given-names>AM</given-names></name> (<year>2015</year>). <article-title>Alzheimer&#x02019;s disease risk genes and mechanisms of disease pathogenesis</article-title>. <source>Biol. Psychiatry</source>
<volume>77</volume>, <fpage>43</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">24951455</pub-id></mixed-citation></ref><ref id="R62"><mixed-citation publication-type="journal"><name><surname>Keren-Shaul</surname><given-names>H</given-names></name>, <name><surname>Spinrad</surname><given-names>A</given-names></name>, <name><surname>Weiner</surname><given-names>A</given-names></name>, <name><surname>Matcovitch-Natan</surname><given-names>O</given-names></name>, <name><surname>Dvir-Szternfeld</surname><given-names>R</given-names></name>, <name><surname>Ulland</surname><given-names>TK</given-names></name>, <name><surname>David</surname><given-names>E</given-names></name>, <name><surname>Baruch</surname><given-names>K</given-names></name>, <name><surname>Lara-Astaiso</surname><given-names>D</given-names></name>, <name><surname>Toth</surname><given-names>B</given-names></name>, <etal/> (<year>2017</year>). <article-title>A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x02019;s Disease</article-title>. <source>Cell</source>
<volume>169</volume>, <fpage>1276</fpage>&#x02013;<lpage>1290.e17</lpage>.<pub-id pub-id-type="pmid">28602351</pub-id></mixed-citation></ref><ref id="R63"><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>EK</given-names></name>, and <name><surname>Choi</surname><given-names>E-J</given-names></name> (<year>2010</year>). <article-title>Pathological roles of MAPK signaling pathways in human diseases</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1802</volume>, <fpage>396</fpage>&#x02013;<lpage>405</lpage>.<pub-id pub-id-type="pmid">20079433</pub-id></mixed-citation></ref><ref id="R64"><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>EK</given-names></name>, and <name><surname>Choi</surname><given-names>E-J</given-names></name> (<year>2015</year>). <article-title>Compromised MAPK signaling in human diseases: an update</article-title>. <source>Arch. Toxicol</source>
<volume>89</volume>, <fpage>867</fpage>&#x02013;<lpage>882</lpage>.<pub-id pub-id-type="pmid">25690731</pub-id></mixed-citation></ref><ref id="R65"><mixed-citation publication-type="journal"><name><surname>Kovacs</surname><given-names>GG</given-names></name> (<year>2015</year>). <article-title>Invited review: Neuropathology of tauopathies: principles and practice</article-title>. <source>Neuropathol. Appl. Neurobiol</source>
<volume>41</volume>, <fpage>3</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">25495175</pub-id></mixed-citation></ref><ref id="R66"><mixed-citation publication-type="journal"><name><surname>Lage</surname><given-names>K</given-names></name>, <name><surname>Karlberg</surname><given-names>EO</given-names></name>, <name><surname>Sterling</surname><given-names>ZM</given-names></name>, <name><surname>Olason</surname><given-names>PI</given-names></name>, <name><surname>Pedersen</surname><given-names>AG</given-names></name>, <name><surname>Rigina</surname><given-names>O</given-names></name>, <name><surname>Hinsby</surname><given-names>AM</given-names></name>, <name><surname>T&#x000fc;mer</surname><given-names>Z</given-names></name>, <name><surname>Pociot</surname><given-names>F</given-names></name>, <name><surname>Tommerup</surname><given-names>N</given-names></name>, <etal/> (<year>2007</year>). <article-title>A human phenome-interactome network of protein complexes implicated in genetic disorders</article-title>. <source>Nat. Biotechnol</source>
<volume>25</volume>, <fpage>309</fpage>&#x02013;<lpage>316</lpage>.<pub-id pub-id-type="pmid">17344885</pub-id></mixed-citation></ref><ref id="R67"><mixed-citation publication-type="journal"><name><surname>Lambert</surname><given-names>J-C</given-names></name>, <name><surname>Ibrahim-Verbaas</surname><given-names>CA</given-names></name>, <name><surname>Harold</surname><given-names>D</given-names></name>, <name><surname>Naj</surname><given-names>AC</given-names></name>, <name><surname>Sims</surname><given-names>R</given-names></name>, <name><surname>Bellenguez</surname><given-names>C</given-names></name>, <name><surname>DeStafano</surname><given-names>AL</given-names></name>, <name><surname>Bis</surname><given-names>JC</given-names></name>, <name><surname>Beecham</surname><given-names>GW</given-names></name>, <name><surname>Grenier-Boley</surname><given-names>B</given-names></name>, <etal/>; <collab>European Alzheimer&#x02019;s Disease Initiative (EADI)</collab>; <collab>Genetic and Environmental Risk in Alzheimer&#x02019;s Disease</collab>; <collab>Alzheimer&#x02019;s Disease Genetic Consortium</collab>; <collab>Cohorts for Heart and Aging Research in Genomic Epidemiology</collab> (<year>2013</year>). <article-title>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x02019;s disease</article-title>. <source>Nat. Genet</source>
<volume>45</volume>, <fpage>1452</fpage>&#x02013;<lpage>1458</lpage>.<pub-id pub-id-type="pmid">24162737</pub-id></mixed-citation></ref><ref id="R68"><mixed-citation publication-type="journal"><name><surname>Langa</surname><given-names>KM</given-names></name>, <name><surname>Larson</surname><given-names>EB</given-names></name>, <name><surname>Crimmins</surname><given-names>EM</given-names></name>, <name><surname>Faul</surname><given-names>JD</given-names></name>, <name><surname>Levine</surname><given-names>DA</given-names></name>, <name><surname>Kabeto</surname><given-names>MU</given-names></name>, and <name><surname>Weir</surname><given-names>DR</given-names></name> (<year>2017</year>). <article-title>A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012</article-title>. <source>JAMA Intern. Med</source>
<volume>177</volume>, <fpage>51</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">27893041</pub-id></mixed-citation></ref><ref id="R69"><mixed-citation publication-type="journal"><name><surname>Langfelder</surname><given-names>P</given-names></name>, and <name><surname>Horvath</surname><given-names>S</given-names></name> (<year>2007</year>). <article-title>Eigengene networks for studying the relationships between co-expression modules</article-title>. <source>BMC Syst. Biol</source>
<volume>1</volume>, <fpage>54</fpage>.<pub-id pub-id-type="pmid">18031580</pub-id></mixed-citation></ref><ref id="R70"><mixed-citation publication-type="journal"><name><surname>Langfelder</surname><given-names>P</given-names></name>, and <name><surname>Horvath</surname><given-names>S</given-names></name> (<year>2008</year>). <article-title>WGCNA: an R package for weighted correlation network analysis</article-title>. <source>BMC Bioinformatics</source>
<volume>9</volume>, <fpage>559</fpage>.<pub-id pub-id-type="pmid">19114008</pub-id></mixed-citation></ref><ref id="R71"><mixed-citation publication-type="journal"><name><surname>Langfelder</surname><given-names>P</given-names></name>, <name><surname>Luo</surname><given-names>R</given-names></name>, <name><surname>Oldham</surname><given-names>MC</given-names></name>, and <name><surname>Horvath</surname><given-names>S</given-names></name> (<year>2011</year>). <article-title>Is my network module preserved and reproducible?</article-title>
<source>PLoS Comput. Biol</source>
<volume>7</volume>, <fpage>e1001057</fpage>.<pub-id pub-id-type="pmid">21283776</pub-id></mixed-citation></ref><ref id="R72"><mixed-citation publication-type="journal"><name><surname>Langfelder</surname><given-names>P</given-names></name>, <name><surname>Mischel</surname><given-names>PS</given-names></name>, and <name><surname>Horvath</surname><given-names>S</given-names></name> (<year>2013</year>). <article-title>When is hub gene selection better than standard meta-analysis?</article-title>
<source>PLoS ONE</source>
<volume>8</volume>, <fpage>e61505</fpage>.<pub-id pub-id-type="pmid">23613865</pub-id></mixed-citation></ref><ref id="R73"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>JK</given-names></name>, and <name><surname>Kim</surname><given-names>N-J</given-names></name> (<year>2017</year>). <article-title>Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer&#x02019;s Disease</article-title>. <source>Molecules</source>
<volume>22</volume>.</mixed-citation></ref><ref id="R74"><mixed-citation publication-type="journal"><name><surname>Liddelow</surname><given-names>SA</given-names></name>, <name><surname>Guttenplan</surname><given-names>KA</given-names></name>, <name><surname>Clarke</surname><given-names>LE</given-names></name>, <name><surname>Bennett</surname><given-names>FC</given-names></name>, <name><surname>Bohlen</surname><given-names>CJ</given-names></name>, <name><surname>Schirmer</surname><given-names>L</given-names></name>, <name><surname>Bennett</surname><given-names>ML</given-names></name>, <name><surname>M&#x000fc;nch</surname><given-names>AE</given-names></name>, <name><surname>Chung</surname><given-names>W-S</given-names></name>, <name><surname>Peterson</surname><given-names>TC</given-names></name>, <etal/> (<year>2017</year>). <article-title>Neurotoxic reactive astrocytes are induced by activated microglia</article-title>. <source>Nature</source>
<volume>541</volume>, <fpage>481</fpage>&#x02013;<lpage>487</lpage>.<pub-id pub-id-type="pmid">28099414</pub-id></mixed-citation></ref><ref id="R75"><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>Y-W</given-names></name>, <name><surname>Chuang</surname><given-names>S-M</given-names></name>, and <name><surname>Yang</surname><given-names>J-L</given-names></name> (<year>2003</year>). <article-title>ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway</article-title>. <source>J. Biol. Chem</source>
<volume>278</volume>, <fpage>21534</fpage>&#x02013;<lpage>21541</lpage>.<pub-id pub-id-type="pmid">12676937</pub-id></mixed-citation></ref><ref id="R76"><mixed-citation publication-type="journal"><name><surname>Logsdon</surname><given-names>BA</given-names></name>, <name><surname>Perumal</surname><given-names>TM</given-names></name>, <name><surname>Swarup</surname><given-names>V</given-names></name>, <name><surname>Wang</surname><given-names>M</given-names></name>, <name><surname>Funk</surname><given-names>C</given-names></name>, <name><surname>Gaiteri</surname><given-names>C</given-names></name>, <name><surname>Allen</surname><given-names>M</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Dammer</surname><given-names>E</given-names></name>, <name><surname>Srivastava</surname><given-names>G</given-names></name>, <etal/> (<year>2019</year>). <article-title>Meta-analysis of the human brain transcriptome identifies heterogeneity across human AD co-expression modules robust to sample collection and methodological approach</article-title>. <source>bioRxiv</source>. <pub-id pub-id-type="doi">10.1101/510420</pub-id>.</mixed-citation></ref><ref id="R77"><mixed-citation publication-type="journal"><name><surname>Love</surname><given-names>JE</given-names></name>, <name><surname>Hayden</surname><given-names>EJ</given-names></name>, and <name><surname>Rohn</surname><given-names>TT</given-names></name> (<year>2015</year>). <article-title>Alternative Splicing in Alzheimer&#x02019;s Disease</article-title>. <source>J. Parkinsons Dis. Alzheimers Dis</source>
<volume>2</volume>, <fpage>6</fpage>.<pub-id pub-id-type="pmid">26942228</pub-id></mixed-citation></ref><ref id="R78"><mixed-citation publication-type="journal"><name><surname>Mackenzie</surname><given-names>IRA</given-names></name>, <name><surname>Neumann</surname><given-names>M</given-names></name>, <name><surname>Baborie</surname><given-names>A</given-names></name>, <name><surname>Sampathu</surname><given-names>DM</given-names></name>, <name><surname>Du Plessis</surname><given-names>D</given-names></name>, <name><surname>Jaros</surname><given-names>E</given-names></name>, <name><surname>Perry</surname><given-names>RH</given-names></name>, <name><surname>Trojanowski</surname><given-names>JQ</given-names></name>, <name><surname>Mann</surname><given-names>DMA</given-names></name>, and <name><surname>Lee</surname><given-names>VMY</given-names></name> (<year>2011</year>). <article-title>A harmonized classification system for FTLD-TDP pathology</article-title>. <source>Acta Neuropathol</source>
<volume>122</volume>, <fpage>111</fpage>&#x02013;<lpage>113</lpage>.<pub-id pub-id-type="pmid">21644037</pub-id></mixed-citation></ref><ref id="R79"><mixed-citation publication-type="journal"><name><surname>McArthur</surname><given-names>S</given-names></name>, <name><surname>Cristante</surname><given-names>E</given-names></name>, <name><surname>Paterno</surname><given-names>M</given-names></name>, <name><surname>Christian</surname><given-names>H</given-names></name>, <name><surname>Roncaroli</surname><given-names>F</given-names></name>, <name><surname>Gillies</surname><given-names>GE</given-names></name>, and <name><surname>Solito</surname><given-names>E</given-names></name> (<year>2010</year>). <article-title>Annexin A1: a central player in the anti-inflammatory and neuroprotective role of microglia</article-title>. <source>J. Immunol</source>
<volume>185</volume>, <fpage>6317</fpage>&#x02013;<lpage>6328</lpage>.<pub-id pub-id-type="pmid">20962261</pub-id></mixed-citation></ref><ref id="R80"><mixed-citation publication-type="journal"><name><surname>McKenzie</surname><given-names>AT</given-names></name>, <name><surname>Moyon</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>M</given-names></name>, <name><surname>Katsyv</surname><given-names>I</given-names></name>, <name><surname>Song</surname><given-names>W-M</given-names></name>, <name><surname>Zhou</surname><given-names>X</given-names></name>, <name><surname>Dammer</surname><given-names>EB</given-names></name>, <name><surname>Duong</surname><given-names>DM</given-names></name>, <name><surname>Aaker</surname><given-names>J</given-names></name>, <name><surname>Zhao</surname><given-names>Y</given-names></name>, <etal/> (<year>2017</year>). <article-title>Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer&#x02019;s disease</article-title>. <source>Mol. Neurodegener</source>
<volume>12</volume>, <fpage>82</fpage>.<pub-id pub-id-type="pmid">29110684</pub-id></mixed-citation></ref><ref id="R81"><mixed-citation publication-type="journal"><name><surname>McKhann</surname><given-names>GM</given-names></name>, <name><surname>Knopman</surname><given-names>DS</given-names></name>, <name><surname>Chertkow</surname><given-names>H</given-names></name>, <name><surname>Hyman</surname><given-names>BT</given-names></name>, <name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr.</suffix></name>, <name><surname>Kawas</surname><given-names>CH</given-names></name>, <name><surname>Klunk</surname><given-names>WE</given-names></name>, <name><surname>Koroshetz</surname><given-names>WJ</given-names></name>, <name><surname>Manly</surname><given-names>JJ</given-names></name>, <name><surname>Mayeux</surname><given-names>R</given-names></name>, <etal/> (<year>2011</year>). <article-title>The diagnosis of dementia due to Alzheimer&#x02019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x02019;s Association workgroups on diagnostic guidelines for Alzheimer&#x02019;s disease</article-title>. <source>Alzheimers Dement</source>. <volume>7</volume>, <fpage>263</fpage>&#x02013;<lpage>269</lpage>.<pub-id pub-id-type="pmid">21514250</pub-id></mixed-citation></ref><ref id="R82"><mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>JA</given-names></name>, <name><surname>Oldham</surname><given-names>MC</given-names></name>, and <name><surname>Geschwind</surname><given-names>DH</given-names></name> (<year>2008</year>). <article-title>A systems level analysis of transcriptional changes in Alzheimer&#x02019;s disease and normal aging</article-title>. <source>J. Neurosci</source>
<volume>28</volume>, <fpage>1410</fpage>&#x02013;<lpage>1420</lpage>.<pub-id pub-id-type="pmid">18256261</pub-id></mixed-citation></ref><ref id="R83"><mixed-citation publication-type="journal"><name><surname>Milton</surname><given-names>RH</given-names></name>, <name><surname>Abeti</surname><given-names>R</given-names></name>, <name><surname>Averaimo</surname><given-names>S</given-names></name>, <name><surname>DeBiasi</surname><given-names>S</given-names></name>, <name><surname>Vitellaro</surname><given-names>L</given-names></name>, <name><surname>Jiang</surname><given-names>L</given-names></name>, <name><surname>Curmi</surname><given-names>PMG</given-names></name>, <name><surname>Breit</surname><given-names>SN</given-names></name>, <name><surname>Duchen</surname><given-names>MR</given-names></name>, and <name><surname>Mazzanti</surname><given-names>M</given-names></name> (<year>2008</year>). <article-title>CLIC1 function is required for beta-amyloid-induced generation of reactive oxygen species by microglia</article-title>. <source>J. Neurosci</source>
<volume>28</volume>, <fpage>11488</fpage>&#x02013;<lpage>11499</lpage>.<pub-id pub-id-type="pmid">18987185</pub-id></mixed-citation></ref><ref id="R84"><mixed-citation publication-type="journal"><name><surname>Mirra</surname><given-names>SS</given-names></name>, <name><surname>Heyman</surname><given-names>A</given-names></name>, <name><surname>McKeel</surname><given-names>D</given-names></name>, <name><surname>Sumi</surname><given-names>SM</given-names></name>, <name><surname>Crain</surname><given-names>BJ</given-names></name>, <name><surname>Brownlee</surname><given-names>LM</given-names></name>, <name><surname>Vogel</surname><given-names>FS</given-names></name>, <name><surname>Hughes</surname><given-names>JP</given-names></name>, <name><surname>van Belle</surname><given-names>G</given-names></name>, and <name><surname>Berg</surname><given-names>L</given-names></name> (<year>1991</year>). <article-title>The Consortium to Establish a Registry for Alzheimer&#x02019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x02019;s disease</article-title>. <source>Neurology</source>
<volume>41</volume>, <fpage>479</fpage>&#x02013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">2011243</pub-id></mixed-citation></ref><ref id="R85"><mixed-citation publication-type="journal"><name><surname>Morris</surname><given-names>JC</given-names></name> (<year>1993</year>). <article-title>The Clinical Dementia Rating (CDR): current version and scoring rules</article-title>. <source>Neurology</source>
<volume>43</volume>, <fpage>2412</fpage>&#x02013;<lpage>2414</lpage>.</mixed-citation></ref><ref id="R86"><mixed-citation publication-type="journal"><name><surname>Mostafavi</surname><given-names>S</given-names></name>, <name><surname>Gaiteri</surname><given-names>C</given-names></name>, <name><surname>Sullivan</surname><given-names>SE</given-names></name>, <name><surname>White</surname><given-names>CC</given-names></name>, <name><surname>Tasaki</surname><given-names>S</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Taga</surname><given-names>M</given-names></name>, <name><surname>Klein</surname><given-names>H-U</given-names></name>, <name><surname>Patrick</surname><given-names>E</given-names></name>, <name><surname>Komashko</surname><given-names>V</given-names></name>, <etal/> (<year>2018</year>). <article-title>A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#x02019;s disease</article-title>. <source>Nat. Neurosci</source>
<volume>21</volume>, <fpage>811</fpage>&#x02013;<lpage>819</lpage>.<pub-id pub-id-type="pmid">29802388</pub-id></mixed-citation></ref><ref id="R87"><mixed-citation publication-type="journal"><name><surname>Munoz</surname><given-names>L</given-names></name>, and <name><surname>Ammit</surname><given-names>AJ</given-names></name> (<year>2010</year>). <article-title>Targeting p38 MAPK pathway for the treatment of Alzheimer&#x02019;s disease</article-title>. <source>Neuropharmacology</source>
<volume>58</volume>, <fpage>561</fpage>&#x02013;<lpage>568</lpage>.<pub-id pub-id-type="pmid">19951717</pub-id></mixed-citation></ref><ref id="R88"><mixed-citation publication-type="journal"><name><surname>Navarro</surname><given-names>V</given-names></name>, <name><surname>Sanchez-Mejias</surname><given-names>E</given-names></name>, <name><surname>Jimenez</surname><given-names>S</given-names></name>, <name><surname>Mu&#x000f1;oz-Castro</surname><given-names>C</given-names></name>, <name><surname>Sanchez-Varo</surname><given-names>R</given-names></name>, <name><surname>Davila</surname><given-names>JC</given-names></name>, <name><surname>Vizuete</surname><given-names>M</given-names></name>, <name><surname>Gutierrez</surname><given-names>A</given-names></name>, and <name><surname>Vitorica</surname><given-names>J</given-names></name> (<year>2018</year>). <article-title>Microglia in Alzheimer&#x02019;s Disease: Activated, Dysfunctional or Degenerative</article-title>. <source>Front. Aging Neurosci</source>
<volume>10</volume>, <fpage>140</fpage>.<pub-id pub-id-type="pmid">29867449</pub-id></mixed-citation></ref><ref id="R89"><mixed-citation publication-type="journal"><name><surname>Nott</surname><given-names>A</given-names></name>, <name><surname>Holtman</surname><given-names>IR</given-names></name>, <name><surname>Coufal</surname><given-names>NG</given-names></name>, <name><surname>Schlachetzki</surname><given-names>JCM</given-names></name>, <name><surname>Yu</surname><given-names>M</given-names></name>, <name><surname>Hu</surname><given-names>R</given-names></name>, <name><surname>Han</surname><given-names>CZ</given-names></name>, <name><surname>Pena</surname><given-names>M</given-names></name>,<name><surname>Xiao</surname><given-names>J</given-names></name>, <name><surname>Wu</surname><given-names>Y</given-names></name>, <etal/> (<year>2019</year>). <article-title>Brain cell type-specific enhancer-promoter interactome maps and disease-risk association</article-title>. <source>Science</source>
<volume>366</volume>,<fpage>1134</fpage>&#x02013;<lpage>1139</lpage>.<pub-id pub-id-type="pmid">31727856</pub-id></mixed-citation></ref><ref id="R90"><mixed-citation publication-type="journal"><name><surname>&#x000d6;hrfelt</surname><given-names>A</given-names></name>, <name><surname>Brinkmalm</surname><given-names>A</given-names></name>, <name><surname>Dumurgier</surname><given-names>J</given-names></name>, <name><surname>Brinkmalm</surname><given-names>G</given-names></name>, <name><surname>Hansson</surname><given-names>O</given-names></name>, <name><surname>Zetterberg</surname><given-names>H</given-names></name>, <name><surname>Bouaziz-Amar</surname><given-names>E</given-names></name>, <name><surname>Hugon</surname><given-names>J</given-names></name>, <name><surname>Paquet</surname><given-names>C</given-names></name>, and <name><surname>Blennow</surname><given-names>K</given-names></name> (<year>2016</year>). <article-title>The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer&#x02019;s disease</article-title>. <source>Alzheimers Res. Ther</source>
<volume>8</volume>, <fpage>41</fpage>.<pub-id pub-id-type="pmid">27716408</pub-id></mixed-citation></ref><ref id="R91"><mixed-citation publication-type="journal"><name><surname>Oprea</surname><given-names>TI</given-names></name>, <name><surname>Bologa</surname><given-names>CG</given-names></name>, <name><surname>Brunak</surname><given-names>S</given-names></name>, <name><surname>Campbell</surname><given-names>A</given-names></name>, <name><surname>Gan</surname><given-names>GN</given-names></name>, <name><surname>Gaulton</surname><given-names>A</given-names></name>, <name><surname>Gomez</surname><given-names>SM</given-names></name>, <name><surname>Guha</surname><given-names>R</given-names></name>, <name><surname>Hersey</surname><given-names>A</given-names></name>, <name><surname>Holmes</surname><given-names>J</given-names></name>, <etal/> (<year>2018</year>). <article-title>Unexplored therapeutic opportunities in the human genome</article-title>. <source>Nat. Rev. Drug Discov</source>
<volume>17</volume>, <fpage>377</fpage>.</mixed-citation></ref><ref id="R92"><mixed-citation publication-type="journal"><name><surname>Parikshak</surname><given-names>NN</given-names></name>, <name><surname>Gandal</surname><given-names>MJ</given-names></name>, and <name><surname>Geschwind</surname><given-names>DH</given-names></name> (<year>2015</year>). <article-title>Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders</article-title>. <source>Nat. Rev. Genet</source>
<volume>16</volume>, <fpage>441</fpage>&#x02013;<lpage>458</lpage>.<pub-id pub-id-type="pmid">26149713</pub-id></mixed-citation></ref><ref id="R93"><mixed-citation publication-type="journal"><name><surname>Parikshak</surname><given-names>NN</given-names></name>, <name><surname>Swarup</surname><given-names>V</given-names></name>, <name><surname>Belgard</surname><given-names>TG</given-names></name>, <name><surname>Irimia</surname><given-names>M</given-names></name>, <name><surname>Ramaswami</surname><given-names>G</given-names></name>, <name><surname>Gandal</surname><given-names>MJ</given-names></name>, <name><surname>Hartl</surname><given-names>C</given-names></name>, <name><surname>Leppa</surname><given-names>V</given-names></name>, <name><surname>Ubieta</surname><given-names>LT</given-names></name>, <name><surname>Huang</surname><given-names>J</given-names></name>, <etal/> (<year>2016</year>). <article-title>Genomewide changes in lncRNA, splicing, and regional gene expression patterns in autism</article-title>. <source>Nature</source>
<volume>540</volume>, <fpage>423</fpage>&#x02013;<lpage>427</lpage>.<pub-id pub-id-type="pmid">27919067</pub-id></mixed-citation></ref><ref id="R94"><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>J-C</given-names></name>, <name><surname>Baik</surname><given-names>SH</given-names></name>, <name><surname>Han</surname><given-names>S-H</given-names></name>, <name><surname>Cho</surname><given-names>HJ</given-names></name>, <name><surname>Choi</surname><given-names>H</given-names></name>, <name><surname>Kim</surname><given-names>HJ</given-names></name>, <name><surname>Choi</surname><given-names>H</given-names></name>, <name><surname>Lee</surname><given-names>W</given-names></name>, <name><surname>Kim</surname><given-names>DK</given-names></name>, and <name><surname>Mook-Jung</surname><given-names>I</given-names></name> (<year>2017</year>). <article-title>Annexin A1 restores A&#x003b2;<sub>1-42</sub> -induced blood-brain barrier disruption through the inhibition of RhoA-ROCK signaling pathway</article-title>. <source>Aging Cell</source>
<volume>16</volume>, <fpage>149</fpage>&#x02013;<lpage>161</lpage>.<pub-id pub-id-type="pmid">27633771</pub-id></mixed-citation></ref><ref id="R95"><mixed-citation publication-type="journal"><name><surname>Pearson</surname><given-names>ES</given-names></name> (<year>1931</year>). <article-title>The test of significance for the correlation coefficient</article-title>. <source>J. Am. Stat. Assoc</source>
<volume>26</volume>, <fpage>128</fpage>&#x02013;<lpage>134</lpage>.</mixed-citation></ref><ref id="R96"><mixed-citation publication-type="journal"><name><surname>Perez-Nievas</surname><given-names>BG</given-names></name>, and <name><surname>Serrano-Pozo</surname><given-names>A</given-names></name> (<year>2018</year>). <article-title>Deciphering the Astrocyte Reaction in Alzheimer&#x02019;s Disease</article-title>. <source>Front. Aging Neurosci</source>
<volume>10</volume>, <fpage>114</fpage>.<pub-id pub-id-type="pmid">29922147</pub-id></mixed-citation></ref><ref id="R97"><mixed-citation publication-type="journal"><name><surname>Ping</surname><given-names>L</given-names></name>, <name><surname>Duong</surname><given-names>DM</given-names></name>, <name><surname>Yin</surname><given-names>L</given-names></name>, <name><surname>Gearing</surname><given-names>M</given-names></name>, <name><surname>Lah</surname><given-names>JJ</given-names></name>, <name><surname>Levey</surname><given-names>AI</given-names></name>, and <name><surname>Seyfried</surname><given-names>NT</given-names></name> (<year>2018</year>). <article-title>Global quantitative analysis of the human brain proteome in Alzheimer&#x02019;s and Parkinson&#x02019;s Disease</article-title>. <source>Sci. Data</source>
<volume>5</volume>, <fpage>180036</fpage>.<pub-id pub-id-type="pmid">29533394</pub-id></mixed-citation></ref><ref id="R98"><mixed-citation publication-type="journal"><name><surname>Power</surname><given-names>JHT</given-names></name>, <name><surname>Shannon</surname><given-names>JM</given-names></name>, <name><surname>Blumbergs</surname><given-names>PC</given-names></name>, and <name><surname>Gai</surname><given-names>W-P</given-names></name> (<year>2002</year>). <article-title>Nonselenium glutathione peroxidase in human brain : elevated levels in Parkinson&#x02019;s disease and dementia with lewy bodies</article-title>. <source>Am. J. Pathol</source>
<volume>161</volume>, <fpage>885</fpage>&#x02013;<lpage>894</lpage>.<pub-id pub-id-type="pmid">12213717</pub-id></mixed-citation></ref><ref id="R99"><mixed-citation publication-type="book"><collab>R Core Team</collab> (<year>2019</year>). <source>R: A Language and Environment for Statistical Computing</source> (<publisher-name>R Foundation for Statistical Computing</publisher-name>).</mixed-citation></ref><ref id="R100"><mixed-citation publication-type="journal"><name><surname>Radford</surname><given-names>RA</given-names></name>, <name><surname>Morsch</surname><given-names>M</given-names></name>, <name><surname>Rayner</surname><given-names>SL</given-names></name>, <name><surname>Cole</surname><given-names>NJ</given-names></name>, <name><surname>Pountney</surname><given-names>DL</given-names></name>, and <name><surname>Chung</surname><given-names>RS</given-names></name> (<year>2015</year>). <article-title>The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia</article-title>. <source>Front. Cell. Neurosci</source>
<volume>9</volume>, <fpage>414</fpage>.<pub-id pub-id-type="pmid">26578880</pub-id></mixed-citation></ref><ref id="R101"><mixed-citation publication-type="journal"><name><surname>Raj</surname><given-names>T</given-names></name>, <name><surname>Li</surname><given-names>YI</given-names></name>, <name><surname>Wong</surname><given-names>G</given-names></name>, <name><surname>Humphrey</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>M</given-names></name>, <name><surname>Ramdhani</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>Y-C</given-names></name>, <name><surname>Ng</surname><given-names>B</given-names></name>, <name><surname>Gupta</surname><given-names>I</given-names></name>, <name><surname>Haroutunian</surname><given-names>V</given-names></name>, <etal/> (<year>2018</year>). <article-title>Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer&#x02019;s disease susceptibility</article-title>. <source>Nat. Genet</source>
<volume>50</volume>, <fpage>1584</fpage>&#x02013;<lpage>1592</lpage>.<pub-id pub-id-type="pmid">30297968</pub-id></mixed-citation></ref><ref id="R102"><mixed-citation publication-type="journal"><name><surname>Readhead</surname><given-names>B</given-names></name>, <name><surname>Haure-Mirande</surname><given-names>J-V</given-names></name>, <name><surname>Funk</surname><given-names>CC</given-names></name>, <name><surname>Richards</surname><given-names>MA</given-names></name>, <name><surname>Shannon</surname><given-names>P</given-names></name>, <name><surname>Haroutunian</surname><given-names>V</given-names></name>, <name><surname>Sano</surname><given-names>M</given-names></name>, <name><surname>Liang</surname><given-names>WS</given-names></name>, <name><surname>Beckmann</surname><given-names>ND</given-names></name>, <name><surname>Price</surname><given-names>ND</given-names></name>, <etal/> (<year>2018</year>). <article-title>Multiscale Analysis of Independent Alzheimer&#x02019;s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus</article-title>. <source>Neuron</source>
<volume>99</volume>, <fpage>64</fpage>&#x02013;<lpage>82.e7</lpage>.<pub-id pub-id-type="pmid">29937276</pub-id></mixed-citation></ref><ref id="R103"><mixed-citation publication-type="journal"><name><surname>Ries</surname><given-names>M</given-names></name>, <name><surname>Loiola</surname><given-names>R</given-names></name>, <name><surname>Shah</surname><given-names>UN</given-names></name>, <name><surname>Gentleman</surname><given-names>SM</given-names></name>, <name><surname>Solito</surname><given-names>E</given-names></name>, and <name><surname>Sastre</surname><given-names>M</given-names></name> (<year>2016</year>). <article-title>The anti-inflammatory Annexin A1 induces the clearance and degradation of the amyloid-&#x003b2; peptide</article-title>. <source>J. Neuroinflammation</source>
<volume>13</volume>, <fpage>234</fpage>.<pub-id pub-id-type="pmid">27590054</pub-id></mixed-citation></ref><ref id="R104"><mixed-citation publication-type="journal"><name><surname>Romanov</surname><given-names>RA</given-names></name>, <name><surname>Zeisel</surname><given-names>A</given-names></name>, <name><surname>Bakker</surname><given-names>J</given-names></name>, <name><surname>Girach</surname><given-names>F</given-names></name>, <name><surname>Hellysaz</surname><given-names>A</given-names></name>, <name><surname>Tomer</surname><given-names>R</given-names></name>, <name><surname>Alp&#x000e1;r</surname><given-names>A</given-names></name>, <name><surname>Mulder</surname><given-names>J</given-names></name>, <name><surname>Clotman</surname><given-names>F</given-names></name>, <name><surname>Keimpema</surname><given-names>E</given-names></name>, <etal/> (<year>2017</year>). <article-title>Molecular interrogation of hypothalamic organization reveals distinct dopamine neuronal subtypes</article-title>. <source>Nat. Neurosci</source>
<volume>20</volume>, <fpage>176</fpage>&#x02013;<lpage>188</lpage>.<pub-id pub-id-type="pmid">27991900</pub-id></mixed-citation></ref><ref id="R105"><mixed-citation publication-type="journal"><name><surname>Ross</surname><given-names>CA</given-names></name>, and <name><surname>Poirier</surname><given-names>MA</given-names></name> (<year>2004</year>). <article-title>Protein aggregation and neurodegenerative disease</article-title>. <source>Nat. Med</source>
<volume>10</volume> (<issue>Suppl</issue>), <fpage>S10</fpage>&#x02013;<lpage>S17</lpage>.<pub-id pub-id-type="pmid">15272267</pub-id></mixed-citation></ref><ref id="R106"><mixed-citation publication-type="journal"><name><surname>Schneider</surname><given-names>JA</given-names></name>, <name><surname>Arvanitakis</surname><given-names>Z</given-names></name>, <name><surname>Leurgans</surname><given-names>SE</given-names></name>, and <name><surname>Bennett</surname><given-names>DA</given-names></name> (<year>2009</year>). <article-title>The neuropathology of probable Alzheimer disease and mild cognitive impairment</article-title>. <source>Ann. Neurol</source>
<volume>66</volume>, <fpage>200</fpage>&#x02013;<lpage>208</lpage>.<pub-id pub-id-type="pmid">19743450</pub-id></mixed-citation></ref><ref id="R107"><mixed-citation publication-type="journal"><name><surname>Seelaar</surname><given-names>H</given-names></name>, <name><surname>Rohrer</surname><given-names>JD</given-names></name>, <name><surname>Pijnenburg</surname><given-names>YAL</given-names></name>, <name><surname>Fox</surname><given-names>NC</given-names></name>, and <name><surname>van Swieten</surname><given-names>JC</given-names></name> (<year>2011</year>). <article-title>Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source>
<volume>82</volume>, <fpage>476</fpage>&#x02013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">20971753</pub-id></mixed-citation></ref><ref id="R108"><mixed-citation publication-type="journal"><name><surname>Seyfried</surname><given-names>NT</given-names></name>, <name><surname>Dammer</surname><given-names>EB</given-names></name>, <name><surname>Swarup</surname><given-names>V</given-names></name>, <name><surname>Nandakumar</surname><given-names>D</given-names></name>, <name><surname>Duong</surname><given-names>DM</given-names></name>, <name><surname>Yin</surname><given-names>L</given-names></name>, <name><surname>Deng</surname><given-names>Q</given-names></name>, <name><surname>Nguyen</surname><given-names>T</given-names></name>, <name><surname>Hales</surname><given-names>CM</given-names></name>, <name><surname>Wingo</surname><given-names>T</given-names></name>, <etal/> (<year>2017</year>). <article-title>A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer&#x02019;s Disease</article-title>. <source>Cell Syst</source>. <volume>4</volume>, <fpage>60</fpage>&#x02013;<lpage>72.e4</lpage>.<pub-id pub-id-type="pmid">27989508</pub-id></mixed-citation></ref><ref id="R109"><mixed-citation publication-type="journal"><name><surname>Shih</surname><given-names>R-H</given-names></name>, <name><surname>Wang</surname><given-names>C-Y</given-names></name>, and <name><surname>Yang</surname><given-names>C-M</given-names></name> (<year>2015</year>). <article-title>NF-kappaB Signaling Pathways in Neurological Inflammation: A Mini Review</article-title>. <source>Front. Mol. Neurosci</source>
<volume>8</volume>,<fpage>77</fpage>.<pub-id pub-id-type="pmid">26733801</pub-id></mixed-citation></ref><ref id="R110"><mixed-citation publication-type="journal"><name><surname>Sims</surname><given-names>R</given-names></name>, <name><surname>van der Lee</surname><given-names>SJ</given-names></name>, <name><surname>Naj</surname><given-names>AC</given-names></name>, <name><surname>Bellenguez</surname><given-names>C</given-names></name>, <name><surname>Badarinarayan</surname><given-names>N</given-names></name>, <name><surname>Jakobsdottir</surname><given-names>J</given-names></name>, <name><surname>Kunkle</surname><given-names>BW</given-names></name>, <name><surname>Boland</surname><given-names>A</given-names></name>, <name><surname>Raybould</surname><given-names>R</given-names></name>, <name><surname>Bis</surname><given-names>JC</given-names></name>, <etal/>; <collab>ARUK Consortium; GERAD/PERADES, CHARGE, ADGC, EADI</collab> (<year>2017</year>). <article-title>Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x02019;s disease</article-title>. <source>Nat. Genet</source>
<volume>49</volume>, <fpage>1373</fpage>&#x02013;<lpage>1384</lpage>.<pub-id pub-id-type="pmid">28714976</pub-id></mixed-citation></ref><ref id="R111"><mixed-citation publication-type="journal"><name><surname>Skaper</surname><given-names>SD</given-names></name>, <name><surname>Facci</surname><given-names>L</given-names></name>, and <name><surname>Giusti</surname><given-names>P</given-names></name> (<year>2013</year>). <article-title>Intracellular ion channel CLIC1: involvement in microglia-mediated &#x003b2;-amyloid peptide(1-42) neurotoxicity</article-title>. <source>Neurochem. Res</source>
<volume>38</volume>, <fpage>1801</fpage>&#x02013;<lpage>1808</lpage>.<pub-id pub-id-type="pmid">23743620</pub-id></mixed-citation></ref><ref id="R112"><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>SK</given-names></name>, <name><surname>Anderson</surname><given-names>HA</given-names></name>, <name><surname>Yu</surname><given-names>G</given-names></name>, <name><surname>Robertson</surname><given-names>AG</given-names></name>, <name><surname>Allen</surname><given-names>SJ</given-names></name>, <name><surname>Tyler</surname><given-names>SJ</given-names></name>, <name><surname>Naylor</surname><given-names>RL</given-names></name>, <name><surname>Mason</surname><given-names>G</given-names></name>, <name><surname>Wilcock</surname><given-names>GW</given-names></name>, <name><surname>Roche</surname><given-names>PA</given-names></name>, <etal/> (<year>2000</year>). <article-title>Identification of syntaxin 1A as a novel binding protein for presenilin-1</article-title>. <source>Brain Res. Mol. Brain Res</source>
<volume>78</volume>, <fpage>100</fpage>&#x02013;<lpage>107</lpage>.<pub-id pub-id-type="pmid">10891589</pub-id></mixed-citation></ref><ref id="R113"><mixed-citation publication-type="journal"><collab>Student</collab>. (<year>1908</year>). <article-title>The probable error of a mean</article-title>. <source>Biometrika</source>
<volume>6</volume>, <fpage>1</fpage>&#x02013;<lpage>25</lpage>.</mixed-citation></ref><ref id="R114"><mixed-citation publication-type="journal"><name><surname>Sugiura</surname><given-names>R</given-names></name>, <name><surname>Satoh</surname><given-names>R</given-names></name>, <name><surname>Ishiwata</surname><given-names>S</given-names></name>, <name><surname>Umeda</surname><given-names>N</given-names></name>, and <name><surname>Kita</surname><given-names>A</given-names></name> (<year>2011</year>). <article-title>Role of RNA-Binding Proteins in MAPK Signal Transduction Pathway</article-title>. <source>J. Signal Transduct</source>
<volume>2011</volume>, <fpage>109746</fpage>.<pub-id pub-id-type="pmid">21776382</pub-id></mixed-citation></ref><ref id="R115"><mixed-citation publication-type="journal"><name><surname>Swarup</surname><given-names>V</given-names></name>, <name><surname>Hinz</surname><given-names>FI</given-names></name>, <name><surname>Rexach</surname><given-names>JE</given-names></name>, <name><surname>Noguchi</surname><given-names>K-I</given-names></name>, <name><surname>Toyoshiba</surname><given-names>H</given-names></name>, <name><surname>Oda</surname><given-names>A</given-names></name>, <name><surname>Hirai</surname><given-names>K</given-names></name>, <name><surname>Sarkar</surname><given-names>A</given-names></name>, <name><surname>Seyfried</surname><given-names>NT</given-names></name>, <name><surname>Cheng</surname><given-names>C</given-names></name>, <etal/>; <collab>International Frontotemporal Dementia Genomics Consortium</collab> (<year>2019</year>). <article-title>Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia</article-title>. <source>Nat. Med</source>
<volume>25</volume>, <fpage>152</fpage>&#x02013;<lpage>164</lpage>.<pub-id pub-id-type="pmid">30510257</pub-id></mixed-citation></ref><ref id="R116"><mixed-citation publication-type="journal"><name><surname>Teng</surname><given-names>EL</given-names></name>, <name><surname>Hasegawa</surname><given-names>K</given-names></name>, <name><surname>Homma</surname><given-names>A</given-names></name>, <name><surname>Imai</surname><given-names>Y</given-names></name>, <name><surname>Larson</surname><given-names>E</given-names></name>, <name><surname>Graves</surname><given-names>A</given-names></name>, <name><surname>Sugimoto</surname><given-names>K</given-names></name>, <name><surname>Yamaguchi</surname><given-names>T</given-names></name>, <name><surname>Sasaki</surname><given-names>H</given-names></name>, <name><surname>Chiu</surname><given-names>D</given-names></name>, <etal/> (<year>1994</year>). <article-title>The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia</article-title>. <source>Int. Psychogeriatr</source>
<volume>6</volume>, <fpage>45</fpage>&#x02013;<lpage>58</lpage>, <comment>discussion 62</comment>.<pub-id pub-id-type="pmid">8054493</pub-id></mixed-citation></ref><ref id="R117"><mixed-citation publication-type="journal"><name><surname>Vinters</surname><given-names>HV</given-names></name> (<year>2015</year>). <article-title>Emerging concepts in Alzheimer&#x02019;s disease</article-title>. <source>Annu. Rev. Pathol</source>
<volume>10</volume>, <fpage>291</fpage>&#x02013;<lpage>319</lpage>.<pub-id pub-id-type="pmid">25387055</pub-id></mixed-citation></ref><ref id="R118"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>J-Z</given-names></name>, and <name><surname>Liu</surname><given-names>F</given-names></name> (<year>2008</year>). <article-title>Microtubule-associated protein tau in development, degeneration and protection of neurons</article-title>. <source>Prog. Neurobiol</source>
<volume>85</volume>,<fpage>148</fpage>&#x02013;<lpage>175</lpage>.<pub-id pub-id-type="pmid">18448228</pub-id></mixed-citation></ref><ref id="R119"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>M</given-names></name>, <name><surname>Roussos</surname><given-names>P</given-names></name>, <name><surname>McKenzie</surname><given-names>A</given-names></name>, <name><surname>Zhou</surname><given-names>X</given-names></name>, <name><surname>Kajiwara</surname><given-names>Y</given-names></name>, <name><surname>Brennand</surname><given-names>KJ</given-names></name>, <name><surname>De Luca</surname><given-names>GC</given-names></name>, <name><surname>Crary</surname><given-names>JF</given-names></name>, <name><surname>Casaccia</surname><given-names>P</given-names></name>, <name><surname>Buxbaum</surname><given-names>JD</given-names></name>, <etal/> (<year>2016</year>). <article-title>Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer&#x02019;s disease</article-title>. <source>Genome Med</source>. <volume>8</volume>, <fpage>104</fpage>.<pub-id pub-id-type="pmid">27799057</pub-id></mixed-citation></ref><ref id="R120"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Cella</surname><given-names>M</given-names></name>, <name><surname>Mallinson</surname><given-names>K</given-names></name>, <name><surname>Ulrich</surname><given-names>JD</given-names></name>, <name><surname>Young</surname><given-names>KL</given-names></name>, <name><surname>Robinette</surname><given-names>ML</given-names></name>, <name><surname>Gilfillan</surname><given-names>S</given-names></name>, <name><surname>Krishnan</surname><given-names>GM</given-names></name>, <name><surname>Sudhakar</surname><given-names>S</given-names></name>, <name><surname>Zinselmeyer</surname><given-names>BH</given-names></name>, <etal/> (<year>2015</year>). <article-title>TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x02019;s disease model</article-title>. <source>Cell</source>
<volume>160</volume>, <fpage>1061</fpage>&#x02013;<lpage>1071</lpage>.<pub-id pub-id-type="pmid">25728668</pub-id></mixed-citation></ref><ref id="R121"><mixed-citation publication-type="journal"><name><surname>Whelan</surname><given-names>JT</given-names></name>, <name><surname>Hollis</surname><given-names>SE</given-names></name>, <name><surname>Cha</surname><given-names>DS</given-names></name>, <name><surname>Asch</surname><given-names>AS</given-names></name>, and <name><surname>Lee</surname><given-names>M-H</given-names></name> (<year>2012</year>). <article-title>Post-transcriptional regulation of the Ras-ERK/MAPK signaling pathway</article-title>. <source>J. Cell. Physiol</source>
<volume>227</volume>, <fpage>1235</fpage>&#x02013;<lpage>1241</lpage>.<pub-id pub-id-type="pmid">21688267</pub-id></mixed-citation></ref><ref id="R122"><mixed-citation publication-type="journal"><name><surname>Wilcoxon</surname><given-names>F</given-names></name> (<year>1945</year>). <article-title>Individual comparisons by ranking methods</article-title>. <source>Biom. Bull</source>
<volume>1</volume>, <fpage>80</fpage>&#x02013;<lpage>83</lpage>.</mixed-citation></ref><ref id="R123"><mixed-citation publication-type="journal"><name><surname>Yoo</surname><given-names>BC</given-names></name>, <name><surname>Cairns</surname><given-names>N</given-names></name>, <name><surname>Fountoulakis</surname><given-names>M</given-names></name>, and <name><surname>Lubec</surname><given-names>G</given-names></name> (<year>2001</year>). <article-title>Synaptosomal proteins, beta-soluble N-ethylmaleimide-sensitive factor attachment protein (beta-SNAP), gamma-SNAP and synaptotagmin I in brain of patients with Down syndrome and Alzheimer&#x02019;s disease</article-title>. <source>Dement. Geriatr. Cogn. Disord</source>
<volume>12</volume>, <fpage>219</fpage>&#x02013;<lpage>225</lpage>.<pub-id pub-id-type="pmid">11244216</pub-id></mixed-citation></ref><ref id="R124"><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>G</given-names></name>, <name><surname>Wang</surname><given-names>L-G</given-names></name>, <name><surname>Han</surname><given-names>Y</given-names></name>, and <name><surname>He</surname><given-names>Q-Y</given-names></name> (<year>2012</year>). <article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title>. <source>OMICS</source>
<volume>16</volume>, <fpage>284</fpage>&#x02013;<lpage>287</lpage>.<pub-id pub-id-type="pmid">22455463</pub-id></mixed-citation></ref><ref id="R125"><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>L</given-names></name>, <name><surname>Petyuk</surname><given-names>VA</given-names></name>, <name><surname>Gaiteri</surname><given-names>C</given-names></name>, <name><surname>Mostafavi</surname><given-names>S</given-names></name>, <name><surname>Young-Pearse</surname><given-names>T</given-names></name>, <name><surname>Shah</surname><given-names>RC</given-names></name>, <name><surname>Buchman</surname><given-names>AS</given-names></name>, <name><surname>Schneider</surname><given-names>JA</given-names></name>, <name><surname>Piehowski</surname><given-names>PD</given-names></name>, <name><surname>Sontag</surname><given-names>RL</given-names></name>, <etal/> (<year>2018</year>). <article-title>Targeted brain proteomics uncover multiple pathways to Alzheimer&#x02019;s dementia</article-title>. <source>Ann. Neurol</source>
<volume>84</volume>, <fpage>78</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">29908079</pub-id></mixed-citation></ref><ref id="R126"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>B</given-names></name>, and <name><surname>Horvath</surname><given-names>S</given-names></name> (<year>2005</year>).<article-title>A general framework for weighted gene co-expression network analysis</article-title>. <source>Stat. Appl. Genet. Mol. Biol</source>
<volume>4</volume>, <fpage>17</fpage>.</mixed-citation></ref><ref id="R127"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>B</given-names></name>, <name><surname>Gaiteri</surname><given-names>C</given-names></name>, <name><surname>Bodea</surname><given-names>L-G</given-names></name>, <name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>McElwee</surname><given-names>J</given-names></name>, <name><surname>Podtelezhnikov</surname><given-names>AA</given-names></name>, <name><surname>Zhang</surname><given-names>C</given-names></name>, <name><surname>Xie</surname><given-names>T</given-names></name>, <name><surname>Tran</surname><given-names>L</given-names></name>, <name><surname>Dobrin</surname><given-names>R</given-names></name>, <etal/> (<year>2013</year>). <article-title>Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x02019;s disease</article-title>. <source>Cell</source>
<volume>153</volume>, <fpage>707</fpage>&#x02013;<lpage>720</lpage>.<pub-id pub-id-type="pmid">23622250</pub-id></mixed-citation></ref><ref id="R128"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Sloan</surname><given-names>SA</given-names></name>, <name><surname>Clarke</surname><given-names>LE</given-names></name>, <name><surname>Caneda</surname><given-names>C</given-names></name>, <name><surname>Plaza</surname><given-names>CA</given-names></name>, <name><surname>Blumenthal</surname><given-names>PD</given-names></name>, <name><surname>Vogel</surname><given-names>H</given-names></name>, <name><surname>Steinberg</surname><given-names>GK</given-names></name>, <name><surname>Edwards</surname><given-names>MSB</given-names></name>, <name><surname>Li</surname><given-names>G</given-names></name>, <etal/> (<year>2016</year>). <article-title>Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse</article-title>. <source>Neuron</source>
<volume>89</volume>, <fpage>37</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">26687838</pub-id></mixed-citation></ref><ref id="R129"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Q</given-names></name>, <name><surname>Ma</surname><given-names>C</given-names></name>, <name><surname>Gearing</surname><given-names>M</given-names></name>, <name><surname>Wang</surname><given-names>PG</given-names></name>, <name><surname>Chin</surname><given-names>L-S</given-names></name>, and <name><surname>Li</surname><given-names>L</given-names></name> (<year>2018</year>). <article-title>Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer&#x02019;s disease</article-title>. <source>Acta Neuropathol. Commun</source>
<volume>6</volume>, <fpage>19</fpage>.<pub-id pub-id-type="pmid">29490708</pub-id></mixed-citation></ref><ref id="R130"><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>BS</given-names></name>, <name><surname>Roundtree</surname><given-names>IA</given-names></name>, and <name><surname>He</surname><given-names>C</given-names></name> (<year>2017</year>). <article-title>Post-transcriptional gene regulation by mRNA modifications</article-title>. <source>Nat. Rev. Mol. Cell Biol</source>
<volume>18</volume>, <fpage>31</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">27808276</pub-id></mixed-citation></ref><ref id="R131"><mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>X</given-names></name>, <name><surname>Lee</surname><given-names>H</given-names></name>, <name><surname>Raina</surname><given-names>AK</given-names></name>, <name><surname>Perry</surname><given-names>G</given-names></name>, and <name><surname>Smith</surname><given-names>MA</given-names></name> (<year>2002</year>). <article-title>The role of mitogen-activated protein kinase pathways in Alzheimer&#x02019;s disease</article-title>. <source>Neurosignals</source>
<volume>11</volume>, <fpage>270</fpage>&#x02013;<lpage>281</lpage>.<pub-id pub-id-type="pmid">12566928</pub-id></mixed-citation></ref><ref id="R132"><mixed-citation publication-type="web"><comment><ext-link ext-link-type="uri" xlink:href="https://agora.ampadportal.org/genes">https://agora.ampadportal.org/genes</ext-link></comment>. <year>2019</year>.</mixed-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><title>Schematic Representation of the Various Analyses Performed in the Study</title><p id="P65">Consensus proteomics modules were generated from five different studies: the Baltimore Longitudinal Study of Aging (BLSA), Adult Changes of Thought (ACT), Mount Sinai Brain Bank (MSBB), Banner Sun Health Research Institute (Banner), and Mayo Clinic Brain Bank (Mayo). Furthermore, the Mayo dataset had matched samples where proteomics and transcriptomics data were available. Comparisons were then made among the consensus proteomics modules (labeled with &#x0201c;C&#x0201d;), Mayo-only proteomics modules (labeled with &#x0201c;P&#x0201d;), and Mayo-matched sample transcriptomics modules (labeled with &#x0201c;T&#x0201d;). Determining the relationship of consensus proteomic modules with other neurodegenerative diseases like frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and Parkinson&#x02019;s disease (PD) was performed using completely separate datasets (UPenn and Emory). Functional annotation of the modules was performed using cell type and Gene Ontology. Common genetic enrichment analysis was used to understand the relationship of modules with causal genetic drivers. The blue dot indicates the location of proteomic brain samples. The green dot indicates location of transcriptomic brain samples.</p></caption><graphic xlink:href="nihms-1710525-f0001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><title>Consensus Proteomics Analyses</title><p id="P66">(A) Consensus proteomics dendrogram showing the proteomics modules from 2 of 5 different proteomics datasets (ACT and BLSA). Color bars below the modules show correlation of disease condition (AD, asymptomatic AD) and biological covariates (age, sex) with the expression of each protein. Red is positive correlation, and blue is anti-correlation.</p><p id="P67">(B) Multidimensional scaling plot on the left demonstrates relationship between consensus proteomics modules and clustering by cell-type relationship. Also shown are the major Gene Ontology enrichment terms for modules. Modules upregulated in AD (green dotted circle) and downregulated in AD (red dotted circle) are shown. On the right is a diagrammatic representation of the trajectory of module eigenprotein with the progression of Alzheimer&#x02019;s disease, highlighting the early and late proteomic modules identified in the study.</p><p id="P68">cTOM, consensus topological overlap matrix; AD, Alzheimer&#x02019;s disease; AsymAD, asymptomatic AD.</p><p id="P69">See also <xref rid="SD4" ref-type="supplementary-material">Figure S1</xref> and <xref rid="SD1" ref-type="supplementary-material">Tables S1</xref>, <xref rid="SD2" ref-type="supplementary-material">S2</xref>, and <xref rid="SD4" ref-type="supplementary-material">S3</xref>.</p></caption><graphic xlink:href="nihms-1710525-f0002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3.</label><caption><title>Early Proteomic Changes in AD</title><p id="P70">(A) Co-expression plot of the C1 module showing the hub proteins in the center.</p><p id="P71">(B&#x02013;D) Plots showing C1 module eigenprotein trajectory with diagnosis (B), CERAD (C), and BRAAK (D) scores in BLSA dataset.</p><p id="P72">(E&#x02013;G) Plots showing C1 module eigenprotein trajectory with diagnosis (E), CERAD (F), and BRAAK (G) scores in validation UPenn dataset.</p><p id="P73">(H) Co-expression plot of the C8 module showing the hub proteins in the center.</p><p id="P74">(I&#x02013;L) Plots showing C8 module eigenprotein trajectory with diagnosis (I), CASI (J), CERAD (K), and BRAAK (L) scores in ACT dataset.</p><p id="P75">(M&#x02013;O) Plots showing C8 module eigenprotein trajectory with diagnosis (M), CERAD (N), and BRAAK (O) scores in validation UPenn dataset.</p><p id="P76">(P) Co-expression plot of the C10 module showing the hub proteins in the center.</p><p id="P77">(Q&#x02013;T) Plots showing C10 module eigenprotein trajectory with diagnosis (Q), CASI (R), CERAD (S), and BRAAK (T) scores in ACT dataset.</p><p id="P78">(U&#x02013;W) Plots showing C10 module eigenprotein trajectory with diagnosis (U), CERAD (V), and BRAAK (W) scores in validation UPenn dataset.</p><p id="P79">For boxplots (B), (E), (I), (M), (Q), and (U), the center line indicates the median, box limits indicate the 25th and 75th percentiles, whiskers extend to the most extreme data point, which is no more than 1.5 times the interquartile range from the median, and outliers are represented by dots.</p><p id="P80">AD, Alzheimer&#x02019;s disease; AsymAD, asymptomatic AD; FTD, frontotemporal dementia; PSP-CBD, progressive supranuclear palsy with corticobasal degeneration; PD, Parkinson&#x02019;s disease; MSA, multiple systems atrophy; ALS, amyotrophic lateral sclerosis. *p &#x0003c; 0.05; **p &#x0003c; 0.01; ***p &#x0003c; 0.005; n.s., non-significant; p, p-value</p><p id="P81">See also <xref rid="SD4" ref-type="supplementary-material">Figures S1</xref>, <xref rid="SD4" ref-type="supplementary-material">S2</xref>, and <xref rid="SD4" ref-type="supplementary-material">S3</xref> and <xref rid="SD2" ref-type="supplementary-material">Tables S2</xref>, <xref rid="SD4" ref-type="supplementary-material">S3</xref>, and <xref rid="SD3" ref-type="supplementary-material">S4</xref>.</p></caption><graphic xlink:href="nihms-1710525-f0003"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4.</label><caption><title>Late Proteomic Changes in AD</title><p id="P82">(A) Co-expression plot of the C2 module showing the hub proteins in the center.</p><p id="P83">(B&#x02013;D) Plots showing C2 module eigenprotein trajectory with diagnosis (B), CERAD (C), and BRAAK (D) scores in Banner dataset.</p><p id="P84">(E&#x02013;G) Plots showing C2 module eigenprotein trajectory with diagnosis (E), CERAD (F), and BRAAK (G) scores in validation UPenn dataset.</p><p id="P85">(H) Co-expression plot of the C3 module showing the hub proteins in the center.</p><p id="P86">(I&#x02013;L) Plots showing C2 module eigenprotein trajectory with diagnosis (I), CASI (J), CERAD (K), and BRAAK (L) scores in ACT dataset.</p><p id="P87">(M&#x02013;O) Plots showing C3 module eigenprotein trajectory with diagnosis (M), CERAD (N), and BRAAK (O) scores in validation UPenn dataset.</p><p id="P88">(P) Co-expression plot of the C4 module showing the hub proteins in the center.</p><p id="P89">(Q&#x02013;S) Plots showing C4 module eigenprotein trajectory with diagnosis (Q), CERAD (R), and BRAAK (S) scores in Banner dataset.</p><p id="P90">(T&#x02013;V) Plots showing C4 module eigenprotein trajectory with diagnosis (T), CERAD (U), and BRAAK (V) scores in validation UPenn dataset.</p><p id="P91">For boxplots (B), (E), (I), (M), (Q), and (T), the center line indicates the median, box limits indicate the 25th and 75th percentiles, whiskers extend to the most extreme data point which is no more than 1.5 times the interquartile range from the median, and outliers are represented by dots.</p><p id="P92">AD, Alzheimer&#x02019;s disease; AsymAD, asymptomatic AD; FTD, frontotemporal dementia; PSP-CBD, progressive supranuclear palsy with corticobasal degeneration; PD, Parkinson&#x02019;s disease; MSA, multiple systems atrophy; ALS, amyotrophic lateral sclerosis. *p &#x0003c; 0.05; **p &#x0003c; 0.01; ***p &#x0003c; 0.005; n.s., non-significant; p, p-value</p><p id="P93">See also <xref rid="SD4" ref-type="supplementary-material">Figures S4</xref> and <xref rid="SD4" ref-type="supplementary-material">S5</xref> and <xref rid="SD2" ref-type="supplementary-material">Tables S2</xref>, <xref rid="SD4" ref-type="supplementary-material">S3</xref>, and <xref rid="SD3" ref-type="supplementary-material">S4</xref>.</p></caption><graphic xlink:href="nihms-1710525-f0004"/></fig><fig id="F5" orientation="portrait" position="float"><label>Figure 5.</label><caption><title>Proteomics and Transcriptomic Analyses</title><p id="P94">(A) For differentially expressed genes in PSP compared to AD (FDR &#x0003c; 0.1) in the Mayo dataset, the PSP-to-AD log2 fold-change at the RNA level correlated with the fold-change at the protein level.</p><p id="P95">(B) Relationship of consensus proteomics, Mayo proteomics, and Mayo transcriptomic modules. The first column is the module name, the second column includes Gene Ontology terms, and the third column includes hub genes of the module. Modules with significant hypergeometric overlap between consensus proteomics and Mayo proteomics and between Mayo proteomics and Mayo transcriptomic are shown. Numbers above connecting lines are the odds ratio of hypergeometric overlap. Bold gene names are hub genes shared across the consensus proteomics, Mayo proteomics, and Mayo transcriptomic modules. A green background denotes upregulation and a red bacgkround denotes downregulation in Alzheimer&#x02019;s disease compared to controls or PSP.</p><p id="P96">(C) Distribution of shortest path between pairs of genes for P3 and T3 modules and for P4 and T1 modules. Infinite distance indicates unconnected gene pairs.</p><p id="P97">See also <xref rid="SD4" ref-type="supplementary-material">Figure S6</xref> and <xref rid="SD4" ref-type="supplementary-material">Tables S5</xref> and <xref rid="SD4" ref-type="supplementary-material">S6</xref>.</p></caption><graphic xlink:href="nihms-1710525-f0005"/></fig><fig id="F6" orientation="portrait" position="float"><label>Figure 6.</label><caption><title>Common Variant Enrichment</title><p id="P98">(A&#x02013;C) Mean scaled enrichment of GWAS hits from AD (<xref rid="R67" ref-type="bibr">Lambert et al., 2013</xref>) and PSP (<xref rid="R51" ref-type="bibr">H&#x000f6;glinger et al., 2011</xref>) in (A) consensus proteomics modules, (B) Mayo proteomics modules, and (C) Mayo transcriptomic modules.</p><p id="P99">(D) Diagram showing enrichment of AD and PSP common variants from GWAS studies in significant consensus proteomics modules, Mayo proteomics modules, and Mayo transcriptomic modules, in addition to their cell-type enrichment.</p></caption><graphic xlink:href="nihms-1710525-f0006"/></fig><table-wrap id="T1" position="float" orientation="portrait"><caption><p id="P100">KEY RESOURCES TABLE</p></caption><table frame="hsides" rules="rows"><colgroup span="1"><col align="left" valign="top" span="1"/><col align="left" valign="top" span="1"/><col align="left" valign="top" span="1"/></colgroup><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">REAGENT or RESOURCE</th><th align="left" valign="middle" rowspan="1" colspan="1">SOURCE</th><th align="left" valign="middle" rowspan="1" colspan="1">IDENTIFIER</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Antibodies</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PLCD1 antibody</td><td align="left" valign="top" rowspan="1" colspan="1">Abcam</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# ab134936; RRID:AB_2857853</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HEPACAM antibody</td><td align="left" valign="top" rowspan="1" colspan="1">Abcam</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# ab130769; RRID:AB_2857854</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PADI2 antibody</td><td align="left" valign="top" rowspan="1" colspan="1">Abcam</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# ab16478; RRID:AB_470249</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GAPDH antibody</td><td align="left" valign="top" rowspan="1" colspan="1">Abcam</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# ab8245; RRID:AB_2107448</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GJA1 antibody</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# C6219; RRID:AB_476857</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Biological Samples</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Postmortem dorsolateral prefrontal and precuneus cortex brain tissue</td><td align="left" valign="top" rowspan="1" colspan="1">Baltimore Longitudinal Study of Aging (BLSA) at Johns Hopkins University</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.hopkinsmedicine.org/research/labs/alzheimers-disease-research-center">https://www.hopkinsmedicine.org/research/labs/alzheimers-disease-research-center</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Postmortem prefrontal cortex brain tissue</td><td align="left" valign="top" rowspan="1" colspan="1">Adult Changes of Thought (ACT) at the University of Washington and Group Health Cooperative of Puget Sound</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://depts.washington.edu/mbwc/adrc/page/neuropathology">http://depts.washington.edu/mbwc/adrc/page/neuropathology</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Postmortem prefrontal cortex brain tissue</td><td align="left" valign="top" rowspan="1" colspan="1">Mount Sinai Brain Bank (MSBB)</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://icahn.mssm.edu/research/nih-brain-tissue-repository">https://icahn.mssm.edu/research/nih-brain-tissue-repository</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Postmortem prefrontal cortex brain tissue</td><td align="left" valign="top" rowspan="1" colspan="1">Banner Sun Health Research Institute (Banner)</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.bannerhealth.com/services/research/locations/sun-health-institute/programs/body-donation">https://www.bannerhealth.com/services/research/locations/sun-health-institute/programs/body-donation</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Postmortem temporal cortex brain tissue</td><td align="left" valign="top" rowspan="1" colspan="1">Mayo Clinic Brain Bank (Mayo)</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.mayo.edu/research/departments-divisions/department-neuroscience-florida/brain-bank">https://www.mayo.edu/research/departments-divisions/department-neuroscience-florida/brain-bank</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Postmortem prefrontal cortex brain tissue</td><td align="left" valign="top" rowspan="1" colspan="1">University of Pennsylvania Brain Bank (UPenn)</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.med.upenn.edu/cndr/biosamples-brainbank.html">https://www.med.upenn.edu/cndr/biosamples-brainbank.html</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Postmortem dorsolateral prefrontal brain tissue</td><td align="left" valign="top" rowspan="1" colspan="1">Emory University (Emory)</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://alzheimers.emory.edu/">http://alzheimers.emory.edu/</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Deposited Data</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baltimore Longitudinal Study of Aging (BLSA) proteomic data</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="R108" ref-type="bibr">Seyfried et al., 2017</xref></td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="doi" xlink:href="10.7303/syn3606086">https://doi.org/10.7303/syn3606086</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Adult Changes of Thought (ACT) proteomic data</td><td align="left" valign="top" rowspan="1" colspan="1">This study</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="doi" xlink:href="10.7303/syn5759376">https://doi.org/10.7303/syn5759376</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mount Sinai Brain Bank (MSBB) proteomic data</td><td align="left" valign="top" rowspan="1" colspan="1">This study</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://repo-prod.prod.sagebase.org/repo/v1/doi/locate?id=syn3159438&#x00026;type=ENTITY">https://repo-prod.prod.sagebase.org/repo/v1/doi/locate?id=syn3159438&#x00026;type=ENTITY</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Banner Sun Health Research Institute (Banner) proteomic data</td><td align="left" valign="top" rowspan="1" colspan="1">This study</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="doi" xlink:href="10.7303/syn7170616">https://doi.org/10.7303/syn7170616</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mayo Clinic Brain Bank (Mayo) proteomic and transcriptomic data</td><td align="left" valign="top" rowspan="1" colspan="1">This study</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="doi" xlink:href="10.7303/syn5550404">https://doi.org/10.7303/syn5550404</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">University of Pennsylvania (UPenn) proteomic data</td><td align="left" valign="top" rowspan="1" colspan="1">This study</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://adknowledgeportal.synapse.org/Explore/Studies?Study=syn21411742">https://adknowledgeportal.synapse.org/Explore/Studies?Study=syn21411742</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Emory proteomic data</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="R97" ref-type="bibr">Ping et al., 2018</xref></td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.synapse.org/#!Synapse:syn10239444">https://www.synapse.org/#!Synapse:syn10239444</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cell type enrichment Markers</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="R128" ref-type="bibr">Zhang et al., 2016</xref></td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.brainrnaseq.org/">http://www.brainrnaseq.org/</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alzheimer&#x02019;s disease GWAS summary statistics</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="R67" ref-type="bibr">Lambert et al., 2013</xref></td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://web.pasteur-lille.fr/en/recherche/u744/igap/igap_download.php">http://web.pasteur-lille.fr/en/recherche/u744/igap/igap_download.php</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Progressive Supranuclear Palsy GWAS summary statistics</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="R51" ref-type="bibr">H&#x000f6;glinger et al., 2011</xref></td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.niagads.org/datasets/ng00045">https://www.niagads.org/datasets/ng00045</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Software and Algorithms</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R</td><td align="left" valign="top" rowspan="1" colspan="1">R Core Team</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.R-project.org/">https://www.R-project.org/</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WGCNA R package</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="R70" ref-type="bibr">Langfelder and Horvath, 2008</xref></td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/WGCNA/index.html">https://cran.r-project.org/web/packages/WGCNA/index.html</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gene Ontology</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://geneontology.org/">http://geneontology.org/</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">igraph R package</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="R18" ref-type="bibr">Csardi and Nepusz, 2006</xref></td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://igraph.org/r/">https://igraph.org/r/</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MAGMA</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="R23" ref-type="bibr">de Leeuw et al., 2015</xref></td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://ctg.cncr.nl/software/magma">https://ctg.cncr.nl/software/magma</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Interactive graphical interface for consensus proteomic network</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://coppolalab.ucla.edu/gclabapps/nb/browser?id=SwarupChangConsensusProteomics">https://coppolalab.ucla.edu/gclabapps/nb/browser?id=SwarupChangConsensusProteomics</ext-link></td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Highlights</title></caption><list list-type="bullet" id="L1"><list-item><p id="P101">We distinguish robust early and late proteomic changes in AD in multiple cohorts</p></list-item><list-item><p id="P102">Changes in dementias are not preserved in other neurodegenerative diseases</p></list-item><list-item><p id="P103">Genetic risk is enriched in glial-immune modules for AD and synaptic for PSP</p></list-item><list-item><p id="P104">Protein expression variance is reflected both at RNA and post-transcriptional levels</p></list-item></list></boxed-text></floats-group></article>